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The glycine receptor is a member of the Cys-loop receptor superfamily of ligand-
gated ion channels and is implicated as a possible therapeutic target for the treatment of 
diseases such as alcoholism and inflammatory pain.  In humans, four glycine receptor 
subtypes (1, 2, , and ) co-assemble to form pentameric channel proteins as either 
homomers or  heteromers.  To date, few agents have been identified that can 
selectively modulate the glycine receptor, especially those possessing subtype specificity.  
We used a cell-based method of phage display panning, coupled with two-electrode 
voltage-clamp electrophysiology in Xenopus laevis oocytes, to identify novel 
heptapeptide modulators of the  glycine receptor.  Peptides were identified that act 
with selectivity on  and compared to glycine receptors.  In addition, 
peptide activity at the glycine receptor decreased when zinc was chelated by tricine, 
similar to previous observations of a decrease in ethanol’s enhancing actions at the 
receptor in the absence of zinc.  Zinc is an allosteric modulator of glycine receptor 
function, enhancing the effects of glycine at nanomolar to low micromolar 
concentrations, and inhibiting its effects at higher concentrations.  As zinc is present 
physiologically at various concentrations within this range, it is capable of influencing 
glycine receptor function, including modulation by other pharmacological agents; 
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however, the magnitude of this effect and its possible relevance are not known.  I 
therefore investigated the utility of previously-described “zinc-enhancement insensitive” 
1 glycine receptor mutants D80A, D80G, and W170S to probe for interactions between 
zinc and other allosteric modulators at the glycine receptor.  Interestingly, I found that 
only the W170S mutation conferred complete abolishment of zinc enhancement across a 
variety of agonist and zinc concentrations.   Using 1 W170S receptors, I established that 
in addition to ethanol, zinc also interacts with inhaled drugs of abuse, but not volatile 
anesthetics, to synergistically enhance channel function.  Additionally, I determined that 
this interaction is abolished at higher zinc concentrations, when receptor-enhancing 
bindings sites are saturated, suggesting a mechanism by which modulators such as 
ethanol and inhalants are capable of increasing receptor affinity for zinc in addition to 
enhancing channel function on their own. 
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Chapter 1: Introduction 
The human nervous system is responsible for integrating and disseminating 
information throughout the body, controlling processes ranging from sensory perception 
and motor control to memory, emotion, and cognition.  This is achieved by means of a 
vast network of billions of interconnected electrically-excitable cells known as neurons.  
Neurons are capable of processing and transmitting information with one another at 
synaptic junctions by both electrical and chemical means.  Neuronal membranes contain 
a variety of ion channels that allow for the regulated movement of ions in and out of the 
cell.  This permits the propagation of electrical signals, known as action potentials, 
towards presynaptic terminals where they trigger the release of chemical signaling 
molecules, or neurotransmitters, into the synaptic cleft.  Neurotransmitters diffuse across 
synapses and convey information to adjacent neurons via the activation of postsynaptic 
neurotransmitter receptors.  Ionotropic neurotransmitter receptors, or ligand-gated ion 
channels, are key mediators of rapid neurotransmission. These receptors are directly 
activated by the binding of their cognate neurotransmitter ligands, resulting in the 
opening of ion conducting pores.  This allows for the rapid conversion of 
neurotransmitter-mediated signaling into changes in membrane potential that affect 
subsequent neuronal activity. 
The Cys-loop receptor superfamily constitutes a major class of ligand-gated ion 
channels involved in rapid excitatory and inhibitory neurotransmission throughout the 
nervous system.  The prototypical member of this family, being the first discovered and 
most studied, is the excitatory cation-selective nicotinic acetylcholine receptor (nAChR).  
Other members include the excitatory, cation-selective serotonin type 3 receptor (5-
HT3R), and the inhibitory, anion-selective channels, the γ-aminobutyric acid type A 
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receptor (GABAAR) and the glycine receptor (GlyR) (Thompson et al., 2010).  These 
receptors are the pharmacological targets for a wide variety of prescribed medications:  
The nAChR, the in vivo target of nicotine, is targeted for smoking cessation and for the 
treatment of cognitive decline in dementias such as Alzheimer’s disease (Dineley et al., 
2015); Antagonists of 5-HT3Rs are powerful anti-emetics often used to treat radiation and 
chemotherapy-induced nausea and vomiting (Thompson and Lummis, 2007); and  
GABAARs are commonly targeted for the treatment of epilepsy, insomnia, and anxiety 
(Tan et al., 2011).  The GlyR, apart from perhaps being involved in the effects of volatile 
anesthetics, is not targeted by any currently-prescribed medications.  However, work over 
the past decade suggests that agents capable of enhancing GlyR function may be able to 
treat chronic inflammatory pain and substance abuse disorders, such as alcoholism (Li et 
al., 2012; Molander et al., 2005; Molander and Soderpalma, 2005a; Xiong et al., 2011, 
2012).  This has led to renewed interest in GlyR pharmacology and a push to develop and 
characterize GlyR modulators that could serve as potential therapeutic agents. 
 
1.1- The Glycine Receptor  
1.1.1- Basic Structure and Function 
The GlyR, like all Cys-loop receptors, is composed of five subunits that form a 
pentamer around a central ion-conducting pore.  Each subunit consists of a large 
extracellular N-terminal domain (ECD), four transmembrane domains (TM1-4), and a 
large, poorly conserved intracellular domain between TM3-4 (Lynch, 2004).  An 
illustration of these structural components can be seen in Fig. 1.1.  The TM2 region of 
each subunit contributes to forming the ion-conducting pore, while the ECD contains 
both the neurotransmitter binding site and the superfamily’s eponymous Cys-loop, 
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formed by a conserved region of 13 amino acids flanked by cysteine residues that form a 
disulfide bond (Lynch 2004; Thompson et al., 2010).  Like GABAARs, the GlyR pore is 
anion permeable, allowing for the conductance of Cl- ions across neuronal membranes in 
vivo.  Since the resting membrane potential of most neurons is generally less negative 
than, or close to, the Cl- reversal potential, GlyR channel opening will result in Cl- influx 
and prevention of action potential firing, leading to its classification as primarily an 












Figure 1.1:  Structural components of the glycine receptor 
Left: Model of the pentameric structure of the 1 GlyR viewed top down from the 
extracellular side of the membrane.  Each color denotes a separate subunit.  Adapted from 
Lynch JW. 2004. Molecular structure and function of the glycine receptor chloride 
channel. Physiol Rev 84, 1051-1095. 
Right: Cartoon representation of a single subunit of the 1 GlyR.  Each amino acid is 
denoted by a circle and the amino acid’s single letter code.  The yellow band represents 
the plasma membrane with the residues of each transmembrane domain clustered within. 








To date, four GlyR subunits, three  and one  have been identified in humans 
(Lynch, 2004).  A fourth  subunit is present in rodents, but is a pseudogene in humans 
(Lynch, 2004).  The -subunits display high levels of homology, sharing 80-90% 
primary amino acid sequence identity, while the  subunit displays ~47% similarity with 
the 1-subunit (Lynch, 2004).  Subunits combine to form functional  homomeric or  
heteromeric channels.  The  subunit, although widely expressed throughout the nervous 
system, is unable to form functional homomeric receptors.  The  subunit is responsible 
for postsynaptic localization of receptors via interactions with the postsynaptic 
scaffolding protein gephyrin; heteromeric receptors are generally considered synaptic 
while homomeric receptors are considered extra-synaptic (Kirsch and Betz, 1995; Meyer 
et al., 1995).  The stoichiometry of heteromeric receptors is still somewhat unclear, with 
recent reports of both 2:3 and 3:2Durisic et al., 2012; Yang et al., 2012.   
As the receptor’s name implies, the amino acid glycine serves as the primary 
ligand responsible for GlyR activation.  In the absence of ligand, channels exist in a 
closed state with little to no spontaneous activity.  Ligand binding occurs at the interface 
of the ECDs of adjacent subunits, allowing for up to 5 possible ligand-binding sites per 
receptor (Brejc et al., 2002).  Agonist binding at a single site results in the simultaneous 
conformational change of all subunits to the activated state (Corringer et al., 2000), and 
single channel conductance is the same at all concentrations of glycine tested (Lape et al., 
2008).  Maximal receptor activation occurs when three or more glycine molecules are 
bound, since the percent time the channel spends in the open state increases with agonist 
concentration (Lewis et al., 2003; Beato et al., 2004).  In addition to glycine, other 
endogenous amino acids such as taurine and -alanine are also capable of activating the 
receptor.  These agonists have lower efficacies than glycine, meaning their binding leads 
to a decreased probability of opening the channel compared to the binding of glycine, 
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lending to their classification as partial GlyR agonists (Lynch et al., 1997).  Studies of 
taurine levels in certain brain regions have led to speculation that taurine, and not glycine, 
may act as the primary ligand of GlyRs found in these areas (Mori et al., 2002; Ericson et 
al., 2006). 
1.1.2 - Allosteric Modulation 
In addition to activation by orthosteric ligands, the GlyR is subject to allosteric 
modulation by a wide variety of compounds including alcohols, inhalants, anesthetics, 
cannabinoids, divalent cations such as zinc, and others (Beckstead et al., 2000; Cheng 
and Kendig, 2002; Downie et al., 1996; Harvey et al., 1999; Laube et al., 1995; Molander 
et al., 2007, 2005; Yamashita et al., 2001; Yevenes and Zeilhofer, 2011).  Most of these 
compounds, particularly the drugs of abuse, are positive allosteric modulators that 
enhance GlyR function, resulting in a left-shift of glycine concentration response curves 
(Yevenes and Zeilhofer, 2011).  These compounds bind the receptor at sites distinct from 
the orthosteric ligand-binding site and enhance ligand-activated currents, but have no 
effect when applied to receptors in the absence of ligand.  Allosteric modulators could 
conceivably enhance receptor function via four possible mechanisms: 1) increasing the 
affinity of the receptor for its orthosteric ligand; 2) increasing the orthosteric ligand’s 
ability to open the channel once bound, i.e., its efficacy; 3) increasing the channel's 
conductance; or 4) by decreasing the rate of orthosteric- ligand-induced receptor 
desensitization.  Zinc and ethanol fail to enhance currents generated by saturating 
concentrations of glycine, suggesting these allosteric modulators increase agonist affinity, 
not efficacy or conductance. Additionally, zinc and ethanol enhance rather than 
antagonize the rates of glycine-mediated desensitization.  Analysis of single channel 
recordings of both zinc and ethanol’s effects on the 1 GlyR shows that these modulators 
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increase channel burst durations but do not significantly affect the probability of within-
burst channel opening (Laube et al., 2000; Welsh et al., 2009).  These data are in 
accordance with a mechanism of modulator action that involves increasing glycine’s 
affinity by decreasing its rate of unbinding from the receptor.  However, currents 
generated by saturating concentrations of the partial agonist taurine are still sensitive to 
enhancement by both compounds, suggesting they do increase taurine’s efficacy and that 
mechanisms of allosteric modulation may depend on the agonist present (Kirson et al., 
2012, 2013).   
Allosteric modulators of the glycine receptor have a variety of putative binding 
sites.  The key residues involved in the binding of the compounds discussed here are 
illustrated in Fig. 1.2.  Drugs of abuse such as ethanol, inhalants, volatile anesthetics, and 
cannabinoids are all thought to have overlapping binding sites within an intersubunit 
water filled cavity involving TM2 and TM3.  A molecular dynamics simulation of 
ethanol’s interactions with residues in this pocket can be seen in Fig. 1.3.  This concept 
was first established by Mihic et al. (1997) who utilized a variety of chimeric receptors 
created from 1 GlyR and GABAA-ρ1 subunits, which have differential sensitivities to 
anesthetics and alcohol, to identify a 45 amino acid region between TM2 and TM3 of the 
1 GlyR that was necessary and sufficient for conferral of receptor enhancement by 
enflurane and ethanol.  Subsequent site-directed mutagenesis of individual residues in 
this region identified residues S267 in TM2 and A288 in TM3 as critical determinants of 
modulator function, suggesting a role in modulator binding (Mihic et al., 1997; Ye et al., 
1998; Yamakura et al., 1999).  This notion was further supported by covalent 
modifications of S267C and A288C mutant receptors with propyl-methanethiosulfonate 
(PMTS), a thiol reagent that forms a disulfide bond with the mutated cysteines to mimic 
modulator binding.  Modification of S267C and A288C residues with PMTS resulted in a 
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permanent enhancement of GlyR function that was not further potentiated by alcohol or 
anesthetics, consistent with molecular occupation of this site conferring GlyR 
enhancement by these compounds (Mascia et al., 2000).  More recently, the existence of 
this binding pocket has been confirmed by the determination of co-crystal structures of 
homologous prokaryotic ligand-gated ion channels bound by a variety of modulators 
(Nury et al., 2011; Sauguet et al., 2013; Spurny et al., 2013).   Site directed mutagenesis 
and NMR studies have also shown that the cannabinoids Δ9-tetrahydrocannabinol and 
cannabidiol (CBD) enhance GlyR function through interaction in this region at S296 
(Xiong et al., 2011, 2012). 
Zinc modulation of the GlyR is unique in that zinc appears to have at least two 
distinct binding sites that confer opposite effects.  Zinc is a biphasic modulator of GlyR 
function, enhancing GlyR currents below 10 M while causing inhibition at higher 
concentrations (Laube et al., 1995).  As mutations that affect zinc-mediated GlyR 
enhancement do not affect inhibition, and vice versa, these sites are believed to be 
completely separate (Miller et al., 2005; Nevin et al., 2003), suggesting the presence of 
both a high-affinity GlyR-enhancing site and a low-affinity GlyR-inhibitory site.  The 
zinc inhibitory binding site is thought to be located at an inter-subunit interface of the 
extracellular domain where zinc is ligated by H107 of one subunit and H109 of the other 
(Nevin et al., 2003).  These residues were initially implicated in a study that found that 
histidine-specific modifying agents were capable of reducing zinc-mediated GlyR 
inhibition (Nevin et al., 2003).  Subsequent site-directed mutagenesis of extracellular 
histidine residues led to the identification of H107 and H109 specifically.  Intersubunit 
binding of zinc at this location was supported by molecular modeling and the fact that the 
reduced zinc inhibition seen in homomeric 1 H107A or H109A GlyRs was rescued 
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when these subunits were co-expressed, consisting with an intersubunit coordination of 
zinc (Nevin et al., 2003).   
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Figure 1.2:  Key residues thought to be involved in allosteric modulation of the 
glycine receptor by zinc and drugs of abuse.   
Zinc has both GlyR-enhancing and inhibitory effects mediated by at least two distinct 
sites in the extracellular domain.  Drugs of abuse enhance GlyR function by interaction 
with a water filled cavity formed by TM2 and TM3.  Adapted from Yevenes GE and 






Figure 1.3:  Molecular dynamic simulation of ethanol binding at the 1 glycine 
receptor 
A 229 ns simulation of ethanol binding to a homology model of the 1 GlyR based on 
the crystal structure of the Gloeobacter violaceus pentameric ligand-gated ion channel. 
Ethanol, depicted as transparent sticks, stably occupied the putative alcohol-binding site 
between transmembrane domains 2 and 3 via hydrogen bonds with S296 (dashed lines) 
and hydrophobic packing with A288, M287 (not shown), and L291.  Adapted from 
Murail et al., 2011. Microsecond simulations indicate that ethanol binds between 
subunits and could stabilize an open-state model of a glycine receptor. Biophys J 100, 
1642-1645 
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The high affinity GlyR-enhancing zinc binding site is less defined.  The first 
proposed binding site involved ECD residue D80, as neutral substitutions of this position 
abolished, or significantly inhibited, zinc-mediated enhancement of glycine-activated 
currents (Laube et al., 2000; Hirzel et al., 2006).  However, one report found that zinc 
potentiation was retained in D80A GlyRs activated by taurine (Lynch et al., 1998).  
Further, this same study found that enhancing concentrations of zinc cause a similar 
increase in the apparent affinity of D80A mutant and wildtype receptors to both glycine 
and taurine in [3H] strychnine binding assays, suggesting zinc retains the ability to bind to 
and affect the channel.  Together, these data suggest that neutral substitutions of D80 
produce an allosteric effect on zinc modulation, as opposed to abolishment of zinc 
binding.  The other proposed GlyR-enhancing zinc binding site involves extracellular 
residues E192 and D194 (Miller et al., 2005).  Neutral substitutions at either position 
completely abolish zinc-enhancement of both glycine and taurine-activated receptors.  
Additionally, covalent modifications of cysteine mutations incorporated at these positions 
with 2-aminoethyl-methanesulfonate (MTSEA), a thiol reactive reagent similar to PMTS, 
were consistent with their role in mediating the binding of enhancing concentrations of 
zinc.  Specifically, the labeling of E192C or D194C with MTSEA produced a 
potentiation of GlyR currents that could not be further enhanced by the application of 
zinc (Miller et al., 2005).  However, zinc-inhibition was retained in labeled mutant 
receptors, providing further evidence for distinct GlyR enhancing and inhibitory zinc 
binding sites (Miller et al., 2005). 
1.1.3 - The Need to Account for the Effects of Zinc in Studies of Glycine 
Receptor Function 
 Rapidly exchangeable zinc (referred to as “free” zinc) is ubiquitous in the central 
nervous system and found tonically in cerebrospinal fluid (CSF) at nanomolar 
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concentrations known to be sufficient to enhance GlyR function (Frederickson et al., 
2006b).  Zinc can also be released synaptically, resulting in higher local concentrations 
reported to range from 1-100 M (Frederickson et al., 2006a; Qian and Noebels, 2005; 
Vogt et al., 2000; Zhang et al., 2016).  Evidence of zinc’s release at glycinergic synapses 
was recently reported by Zhang et al. (2016) who found that local zinc concentrations can 
reach up to 1 M after presynaptic stimulation of primary cultured rat embryonic 
glycinergic neurons.  Additionally, zinc modulation appears to be important for proper 
GlyR function as mutations that result in the abolishment of zinc-enhancement have been 
shown to cause human hyperkplexia and hyperkplexia-like phenotypes in rodents (Hirzel 
et al., 2006; Zhou et al., 2013). 
  In addition to its presence in vivo, zinc is a common contaminant that can be 
found in labware and reagents at concentrations capable of affecting GlyR function 
(Cornelison and Mihic, 2014; Kay, 2004).  We previously determined that our 
electrophysiological buffers contain approximately 45 nM zinc (Cornelison and Mihic, 
2014).  Other studies have reported approximately 200-800 nM contaminating zinc in 
electrophysiological solutions (Thio and Zhang, 2006; Wilkins and Smart, 2002; Zheng 
et al., 1998).  All of these concentrations are within the GlyR-enhancing range suggesting 
that, without accounting for the effect of contaminating zinc, one cannot assume that 
responses elicited by glycine alone are not necessarily also partially due to some level of 
allosteric modulation by zinc.  To complicate matters further, recent reports have shown 
that the degree of ethanol enhancement of GlyR function is dependent on the 
concentration of zinc present.  Specifically, chelation of contaminating zinc significantly 
decreased ethanol enhancement of GlyR function while the addition 50-500 nM zinc 
significantly increased ethanol enhancement of GlyR function (McCracken et al., 2010; 
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2013a,b).  Since contaminating zinc is seldom accounted for in studies of GlyR function, 
the extent of zinc-dependence in the action other GlyR modulators is unknown. 
 
1.2- The Glycine Receptor as Therapeutic Target  
1.2.1 – Alcoholism 
Due to its ease of access, and the relative lack of social stigma attached to its use, 
alcohol has become one of the most widely used drugs of abuse.  The 2014 National 
Survey on Drug Use and Health conducted by the Substance Abuse and Mental Health 
Services Administration reported that 16.3 million, or 6.8%, of adults over the age of 18  
in the U.S. suffered from alcohol use disorder.  Further, nearly 679,000, or 2.7%, of 
adolescents were also reported suffer from alcohol use disorder.   Between 2006 and 
2010, the U.S. saw an average of 87,790 alcohol-associated deaths a year with nearly 1 in 
10 deaths of working-age adults (20-64 years of age) attributed to excessive alcohol 
consumption (Stahre et al., 2014).  Additionally, excessive alcohol consumption was 
estimated to cost the U.S. $249 billion in 2010 (Sacks et al., 2015).  Ethanol, the active 
ingredient in alcoholic beverages, is a central nervous system (CNS) depressant that is 
believed to exert its effects through a large number of molecular targets (Harris et al., 
2008).  The non-specific nature of ethanol’s actions has made it difficult to determine 
viable therapeutic targets for pharmacological intervention.   
Like other drugs of abuse, ethanol increases dopamine signaling from the ventral 
tegmental area (VTA) to the nucleus accumbens (nAc), an effect thought to be critical in 
the rewarding properties of drugs of abuse (Gonzales et al., 2004).  Multiple lines of 
evidence now suggest that ethanol enhancement of GlyRs located on accumbal 
GABAergic neurons disinhibit dopaminergic neurons, resulting in ethanol-mediated 
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dopamine release.  Activation of presynaptic GlyRs on GABAergic interneurons in the 
VTA has been shown to facilitate the firing of dopaminergic cells (Ye et al., 2004). 
Additionally, infusion of glycine into the nAc increased dopamine concentration, similar 
to alcohol, and alcohol-induced dopamine release was blocked by the GlyR-specific 
competitive antagonist strychnine (Molander and Soderpalm 2005a,b; Molander et al., 
2005).  Further, infusion of glycine into the nAc or microinjection of glycine into the 
VTA have both been shown to selectively decrease ethanol consumption and preference 
in rodents (Li et al., 2012; Molander and Soderpalm, 2005a,b; Molander et al., 2005).  
Moreover, the glycine reuptake inhibitor Org 25935, which increases GlyR function by 
preventing reuptake of extracellular glycine, increases dopamine levels in the nAc, with 
decreased alcohol consumption and preference seen in rodents (Lidö et al., 2009, 2010; 
Molander et al., 2007).  These studies suggest that GlyR-enhancing agents may be able to 
satiate cravings for alcohol via increased dopamine release in the absence of alcohol 
consumption.  A recent clinical trial found no benefit of Org 25935 over placebo in the 
preventions of relapse in alcohol dependent patients (de Bejczy et al., 2014).  However, 
due to a number of limitations within the trial itself, research is expected to continue on 
this molecule and other GlyR-enhancing agents. 
1.2.2 – Chronic Inflammatory Pain 
The 3 GlyR is abundantly expressed in lamina II neurons of the spinal dorsal 
horn, where the majority of nociceptive afferents terminate (Harvey et al., 2004).  
Increased function of these receptors is thought to gate the relay of nociceptive signaling 
into higher brain regions (Ahmadi et al., 2002; Foster et al., 20015; Harvey et al., 2004, 
2009).  Prostaglandins have long been recognized as important mediators of 
inflammatory pain (O’Banion 1999).  Prostaglandin E2 (PGE2) has been shown to 
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selectively mediate inflammatory pain via protein kinase A (PKA)-dependent inhibition 
of 3 GlyR function (Ahmadi et al., 2002; Harvey et al., 2004, 2009; Hosl et al., 2006).  
Specifically, PGE2 activation of PKA results in phosphorylation of GlyR residues in the 
intracellular loop that have been shown to induce both receptor internalization and 
conformational changes that decrease receptor sensitivity to agonist (Han et al., 2013; 
Huang et al., 2007; Velázquez-Flores and Saleda 2011).   
Recently, the cannabinoid dehydroxyl-CBD (DH-CBD) was shown to rescue 
PGE2 inhibition of 3 GlyR function (Xiong et al., 2012).  Additionally, cannabinoid-
induced analgesia is thought to be primarily mediated through positive allosteric 
modulation of GlyRs (Xiong et al., 2011, 2012).  Cannabinoid-induced analgesia in 
rodent models of thermal and mechanical pain was abolished in 3 GlyR knockout mice 
but unchanged in cannabinoid receptor type 1 and 2 knockout mice (Xiong et al., 2011).  
There was also a strong positive correlation between the analgesic potency of 11 different 
cannabinoids and their abilities to potentiate the 3 GlyR, but there was no correlation 
seen between their analgesic effects and their affinities for cannabinoid receptors (Xiong 
et al., 2011).   Further, it was shown that a DH-CBD analogue that antagonizes DH-CBD 
enhancement of GlyR function also antagonizes DH-CBD-induced analgesia in rodent 
models of inflammatory pain (Xoing et al., 2012).  Interestingly, there was no loss in the 
analgesic effect of DH-CBD with repeated administrations over multiple days, suggesting 
a lack of tolerance development for this molecule.  This is especially promising as 
tolerance is a large problem with currently prescribed medications for chronic pain.  
Taken together, these data suggest agents capable of enhancing 3 GlyR function could 
serve as valuable novel therapeutics in the treatment of chronic inflammatory pain.   
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1.3 - Phage Display  
 Historically, the discovery of novel drugs for the treatment of disease has relied 
upon serendipity or the isolation of active compounds in known natural remedies and 
their subsequent chemical modification.  However, the development of high-throughput 
drug screening platforms and an ever-increasing body of knowledge of the molecular 
basis of disease has allowed for a more rational approach to drug discovery (Drews, 
2000).  Phage display has long been utilized to identify peptides, antibodies, or other 
proteins capable of binding to specific molecular targets (Molek et al., 2011; Nixon et al., 
2014).  Now considered a crucial drug discovery platform, phage display has contributed 
to the development of a variety of approved medications including the popular arthritis 
treatment Humira, the protective anthrax antibody ABthrax, the lupus medication 
Benlysta, and others (Nixon et al., 2014).   
Phage display involves the production of large libraries of bacteriophage that have 
been genetically modified to display peptides as fusion proteins with various phage coat 
proteins.  A variety of phage display platforms have been developed.  The most common 
systems employ fusions or peptides or antibodies to minor coat proteins of the Ff family 
of filamentous phage (M13, Fd, f1) (Buckler et al., 2012; Nixon et al., 2014).  Phage 
display libraries of large molecular diversity have been generated with the ability to 
display up to 1011 distinct peptide sequences (Sidhu et al., 2000).  Libraries are ‘panned’ 
against a protein target, generally immobilized to the surface of a plate, and phage that 
bind specifically to the target can be isolated and amplified by outgrowth in bacteria. The 
direct physical linkage of the displayed protein to the gene that encodes it facilitates easy 
identification of the peptides responsible for the binding of phage to molecular targets.  
Over several rounds of selection and outgrowth amplification, target-specific peptides 
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can be readily selected from a phage library.  An illustration of a basic phage display 
procedure can be seen in Fig. 1.4.   
  The affinity of selected peptides or proteins for their targets depends largely 
upon the type of library and methods used.  The valence of displayed peptides has a 
strong effect on subsequent peptide affinity and depends on what phage coat protein the 
peptide is fused to, ranging from five to thousands of copies per phage using standard 
platforms (Molek et al., 2011).  Polyvalent display leads to an avidity effect where the 
apparent affinity of the phage-peptide complex, containing multiple copies of the peptide 
that are all capable of binding the target, is greater than that of a single peptide alone 
(Lowman, 1997).  This can be overcome through the utilization of a phagemid-display 
system.  This method utilizes the transformation of phagemids encoding the displayed 
fusion proteins into bacteria.  Subsequent infection of bacteria with “helper-phage” 
provides the remainder of genes necessary for mature phage production.  The competition 
of phagemid encoded peptide-displaying coat proteins with wildtype proteins results in a 
decreased valency of the displayed peptide and can be optimized to result in monovalent 
display (Qi et al., 2012).  Other factors that influence the affinity of identified peptides 
for target include the concentration of target used in panning, the amount of time allowed 
for phage binding, and the stringency of subsequent wash steps.  Generally, naïve 
libraries result in the identification of peptides or proteins that can bind with mid nM - 
high M affinities, although sub-nM affinity has been achieved (Buckler et al., 2012; 
Lowman, 1997; Molek et al., 2011; Nixon et al., 2014; Qi et al., 2012).  In order to obtain 
binding affinities appropriate for therapeutic use (low nM), researchers typically employ 
an iterative affinity maturation process in which the sequences of identified peptides are 





Figure 1.4: Illustration of a basic phage display procedure 
A) Cartoon model depicting a basic bacteriophage used in phage display.  The gene 
encoding a displayed peptide (pink) is cloned into the pIII minor coat protein.  B)  
Overview of a basic phage display panning procedure: 1) A phage library containing up 
to 1011 unique clones is incubated with target antigen. 2)  Unbound phage are removed by 
a series of wash steps. 3) Bound phage are eluted, often through a reduction in the pH. 4) 
Eluted phage are used to infect bacteria.  5)  Phage replicate in bacteria, amplifying the 
number of phage that display peptides capable of binding to the target antigen.  These 
phage can then be isolated and used in subsequent rounds of panning to increase the 
specificity and affinity of identified peptides.  Standard phage display procedures employ 
a series of 3-5 rounds of panning prior to characterization of selected peptides.  The 
sequence of selected peptides are often used to design new libraries for subsequent series 
of panning in order to further increase the affinities of identified peptide for their target.  
Adapted from Nixon et al., 2014. Drugs derived from phage display: from candidate 




Standard phage display procedures call for the purification and fixation of target 
proteins to microtiter plates, complicating the selection of peptides capable of affecting 
the function of integral membrane proteins (Molek et al., 2011).  This is partially due to 
the fact that the transmembrane regions of these proteins are extremely hydrophobic and 
difficult to purify.  This can be overcome through the targeting of smaller recombinant 
protein fragments, such as the extracellular domains, that can easily be purified and fixed 
to a plate (Su et al., 2005; Hetian et al. 2002; Molek et al., 2011).  However, multimeric 
membrane proteins, such as ligand-gated ion channels, require interactions between 
multiple protein subunits for the maintenance of their proper functional conformation.  
For this purpose, phage display procedures have been developed in which phage libraries 
are panned against targets expressed in cultured cells, ensuring their proper functional 
conformation (Arita et al., 2016; Tipps et al., 2010; Wang et al., 2006; Watters et al., 
1997).  However, in order to avoid the selection of phage capable of binding non-
specifically to the cells themselves, a negative selection step is often required (Molek et 
al., 2011).  This involves a process referred to as ‘subtractive panning,’ in which phage 
libraries are washed over cells that do not express the target of interest prior to positive 
selection against target-expressing cells.  This allows for the depletion of phage clones 
from the library that would be capable of nonspecifically binding endogenous proteins 
found on the cells utilized for expression of the target protein.  Tipps et al. (2010) 
reported the first adaptation of a phage display procedure to target a ligand-gated ion 
channel, specifically the GlyR.  This study employed a cell based phage display 
procedure in which GlyRs were overexpressed in human embryonic kidney (HEK) cells 
for positive selection while subtractive panning was carried out in un-transfected HEK 
cells.  Using this method, they were able to identifying peptides capable of selectively 
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modulating GlyR function at low M concentration while minimally affecting the closely 
related GABAAR.     
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Chapter 2: Materials and Methods 
Materials and methods common among the studies contained within this 
dissertation are presented below.  Methods that are specific to a particular study can be 
found within the materials and methods section of the appropriate chapter. 
 
2.1- Buffers and reagents 
All chemicals were obtained from Sigma-Aldrich (St. Louis, MO) except for 
isoflurane which was obtained from Marsam Pharmaceutical Inc. (Cherry Hill, NJ), 
tricaine which was obtained from Western Chemical, Inc. (Ferndale, WA), and synthetic 
peptides which were obtained from Peptide 2.0 (Chantilly, VA).   
 
All buffers were made in ultrapure diH2O and pH adjusted with NaOH as 
necessary.  Buffer recipes were as follows: 
Modified Barth’s Saline (MBS) — 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 10 mM 
HEPES, 0.82 mM, MgSO4·7H2O, 0.33 mM Ca(NO3)2, and 0.91 mM CaCl2, pH 7.5 
Isolation Media — 108 mM NaCl, 1 mM EDTA, 2 mM KCl, and 10 mM HEPES, pH 
7.5 
Collagenase Solution — 83 mM NaCl, 2 mM MgCl2, and 5 mM HEPES, 0.5 mg/ml 
Sigma Type 1A collagenase, pH 7.5 
Incubation Media — MBS + 2 mM sodium pyruvate, 0.5 mM theophylline, 10 U/ml 
penicillin, 10 mg/l streptomycin, and 50 mg/l gentamicin 
 
 23 
2.2- Xenopus laevis ooctye isolation and cDNA injection 
Xenopus laevis were obtained from Nasco (Fort Atkinson, WI) and housed at 
19°C on a 12 hr light/dark cycle.  Oocytes were surgically obtained in accordance with 
the Association for Assessment and Accreditation of Laboratory Animal Care 
regulations.  Briefly, frogs were anesthetized with tricaine and a small incision was made 
in the lower abdomen with a no. 10 scalpel.  A small portion of the ovaries was removed 
with forceps and stored in incubation media.  Incisions were then closed with sutures and 
frogs were allowed to recover in isolation for a minimum of three hours before being 
returned to their home tanks.  Frogs were allowed to fully recover in their home tanks for 
at least 30 days prior to subsequent surgeries.  After three surgeries, frogs were 
euthanized by an overdose of tricaine. 
Harvested oocytes were placed in hypertonic isolation media in order to slightly 
shrink the oocyte for easier removal of protective membranes.  Forceps were used to 
manually remove the thecal and epithelial layers from stage V and VI oocytes before 
removal of the follicular layer by a 10 min incubation in 0.5 mg/ml type 1A collagenase.  
Isolated oocytes were then washed and stored in incubation media up to 24 hr prior to 
cDNA injection. 
A 32.2 nl sample of 50 ng/l of the appropriate GlyR cDNA, contained within a 
modified pBK-cytomegalovirus vector (Mihic et al., 1997),  was injected into the animal 
pole of each oocyte using a micropipette (10-15 m tip size) attached to an electronically 
activated microdispenser.  When expression of heteromeric receptors was desired, cDNA 
was injected at a 1:20  ratio (50 ng/L total).  Oocytes were stored individually at 
room temperature in 96-well plates containing incubation media sterilized by passage 
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through a 0.22 M filter.  Oocytes expressed GlyRs within ~24 hr and all 
electrophysiological recordings were made within 5 days of oocyte isolation.   
 
2.3- Two-electrode voltage-clamp electrophysiology 
Oocytes were placed in a 100 l bath with the animal poles facing upwards and 
impaled with two high-resistance (0.5-10 MΩ) glass electrodes filled with 3 M KCl.  
Oocytes were perfused with MBS at a rate of 2 ml/min through 18-gauge polyethylene 
tubing using a Masterflex peristaltic pump (Cole Parmer Instrument Co., Vernon Hills, 
IL) and voltage-clamped at -70 mV using an OC-725C oocyte clamp (Warner 
Instruments, Hamden, CT).   One electrode is used to continually measure the voltage of 
the cell while the other electrode injects current in order to maintain the desired potential.  
When GlyRs open, chloride ion flux is detected by the voltage electrode, resulting in an 
injection of current in order to maintain the desired voltage.  The magnitude of the 
injected current is equal and opposite to the flow of ions through the channel, allowing 
for accurate quantification of GlyR activity. Currents were measured at a rate of 1 kHz 
using a Powerlab 4/30 digitizer with LabChart version 7 software (ADInstruments, Bella 
Vista, NSW, Australia). 
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Chapter 3: Identification and characterization of peptide 
modulators of the glycine receptor1 
3.1- Introduction 
The Cys-loop receptor superfamily constitutes a major class of ligand-gated ion 
channels involved in fast inhibitory and excitatory neurotransmission throughout the 
central nervous system and periphery.  Due to their involvement in a variety of central 
nervous system disorders, several members of this receptor superfamily serve as targets 
both for compounds in clinical use, as well as investigational agents (Dineley et al., 2015; 
Nys et al., 2013).  In particular, the GlyR has been identified as a potential target for a 
variety of therapeutic applications, including the treatment of inflammatory pain and 
alcoholism (Li et al., 2012; Molander et al., 2005; Molander and Soderpalma, 2005a; 
Xiong et al., 2011, 2012).   
Although GlyRs predominate in the brain stem and spinal cord, they are also 
expressed in higher brain regions such as the nucleus accumbens, frontal cortex, and 
hippocampus (Jonsson et al., 2012; 2009; Molander and Söderpalm, 2005b).  A variety of 
drugs of abuse, including alcohol, inhalants and volatile anesthetics enhance GlyR 
function at concentrations that are achieved in vivo (Lynch, 2004; Molander et al., 2005; 
Xiong et al., 2009).  Enhanced activation of these channels through positive allosteric 
modulation effectively treats inflammatory pain in rodents and may aid in the treatment 
of addictions such as alcoholism, through modulation of dopamine release (Molander et  
 __________ 
 
1Portions of this chapter have previously been published in European Journal of 
Pharmacology. Cornelison, G.L., Pflanz, N.C., Tipps, M.E., Mihic, S.J. 2016. 
Identification and characterization of heptapeptide modulators of the glycine 
receptor. Eur J Pharmacol 780, 252-259. Copyright © 2016 Elsevier Ltd. All 
rights reserved.  G.L.C. conducted or supervised all experiments and wrote the 
manuscript. 
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al., 2005; Molander and Soderpalm, 2005 a,b; Xiong et al., 2012).  However, while 3- 
containing receptors are thought to predominate in GlyR-mediated analgesia, it is not 
entirely clear which subtypes are responsible for the behavioral and dopamine-
modulating effects of alcohol.  While and containing receptors seem to be the 
most likely in vivo targets of alcohol (Blednov et al., 2015), there would be considerable 
utility in the development of GlyR modulators with subunit selectivity, to definitively 
determine the relative contributions of each particular subtype to alcohol’s 
pharmacological effects.  Our previous work validated the use of phage display for the 
discovery of novel peptide modulators of the GlyR (Tipps et al., 2010).  In this chapter, 
we expand on these studies by identifying and characterizing the action of peptides with 
selectivity for  and  over containing GlyRs and identify several possible 
amino acid consensus sequences within the heptapeptides.  Interestingly, the actions of 
these peptides appear to be zinc-dependent.   This zinc dependence was also previously 
shown to affect alcohol modulation of the GlyR (McCracken et al., 2010), suggesting that 
the presence of zinc may be necessary for efficient modulation of GlyR activity by 
allosteric modulators.   
 
3.2- Materials and Methods 
3.2.1- Peptide reagents 
Peptides were synthesized as HCl salts at 98% purity by Peptide 2.0 Inc. 
(Chantilly, VA).  Peptides were received as a lyophilized powder and suspended at a 
concentration of 10 mM in ultrapure H2O, based on the theoretical peptide molecular 
weight and the dry weight of lyophilized peptide material.  Suspended peptides were 
stored as single-use aliquots at -20°C for up to 4 weeks before use. 
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3.2.2- Human Embryonic Kidney (HEK) Cell Culture and Expression of 
Glycine Receptors 
HEK 293 cells were obtained from the American Type Culture Collection and 
grown according to standard procedures (Freshney, 2002).  Briefly, cells were cultured at 
37°C and 5% CO2 in Gibco® Dulbecco’s modified Eagle’s medium with L-glutamine, 
sodium pyruvate, and 10% fetal bovine serum (Thermo-Fisher Scientific, Waltham, MA).  
Cells were split every 5 days with Gibco®  trypsin-EDTA (Thermo-Fisher Scientific) up 
to 25 times, after which new aliquots of early-passage cells were started.  Cells were 
transfected with 4 g of GlyR , , or  cDNA (1:20  ratio) in modified 
pBK-cytomegalovirus vectors (Mihic et al., 1997) using PolyFect reagent (Qiagen, 
Valencia, CA).  All cells were incubated for at least 48 hr before use in panning. 
3.2.3- Phage Display  
The phage display procedure was modified from the manufacturer’s instructions 
and consisted of two separate panning series, D7.1 and D7.2.  Each series was identical 
except for the subtractive panning step against negative selection cells.  This step allows 
for the depletion of phage capable of binding non-specifically to either endogenous HEK 
cell membrane proteins or to the overexpressed negative selection receptors, thereby 
increasing the specificity of obtained peptides. Subtractive panning for series D7.1 
consisted of washing the phage library over negative selection HEK 293 cells 
expressing GlyRs while D7.2 consisted of a pair of washes of library over negative 
selection HEK 293 cells expressing  followed by HEK 293 cells expressing   
GlyRs.  On panning day 1, plates of positive and negative selection HEK 293 cells were 
washed three times with 0.01 M phosphate-buffered saline (PBS) containing 8.2 mM 
NaPO4, 1.5 mM KH2PO4, 137 mM NaCl, and 2.7 mM KCl with 1.5% bovine serum 
albumin (BSA) and 0.1% Tween (PBS/BSA+T).  Next, the Ph.D.-7 phage library (New 
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England Biolabs, Ipswich, MA) was diluted to ~1011 plaque forming units (PFU) in 1 ml 
of PBS/BSA+T, applied to negative selection cells, and rocked gently at room 
temperature for 30 min.  Phage capable of binding non-specifically to endogenous HEK 
293 proteins or to the expressed negative selection receptors were thereby removed by 
this subtractive panning step and the remaining phage in the supernatant were transferred 
to positive selection HEK 293 cells expressing  GlyRs and rocked gently for 60 min.  
Phage unable to bind to the positive selection target were discarded with the supernatant 
and phage bound to  GlyRs were eluted in 1 mL of phage elution buffer (0.2 M 
glycine-HCl + 1 mg/ml BSA, pH 2.0) by gentle rocking for 10 min.  Eluate was removed 
and neutralized with 150 L of 1 M Tris-HCl (pH 9.0).   
10 L of eluate was used to determine phage titer and the remainder was used to 
infect 20 mL of mid-log phase Escherichia coli ER2738 in LB broth.  After 4.5 hr of 
incubation at 37°C, the E. coli-phage mixture was pelleted at 10,000 rpm for 10 min at 
4°C.  The supernatant was transferred to a fresh tube and re-spun.  The upper 80% of the 
supernatant was again transferred to a fresh tube, and one-sixth volume of polyethylene 
glycol/NaCl (20% w/v polyethylene glycol 8000 and 2.5 M NaCl) was added.  Phage 
were allowed to precipitate overnight at 4°C. 
On panning day 2, polyethylene glycol precipitates were spun at 10,000 rpm for 
15 min at 4°C.  The supernatant was discarded and the precipitate was spun again.  
Residual supernatant was removed using a pipette and the phage-containing pellet was re-
suspended in 1 mL of Tris-buffered saline (50 mM Tris-HCl (pH 7.5) and 150 mM 
NaCl), transferred to a 1.7 mL microcentrifuge tube and spun at 10,000 rpm for 5 min at 
4°C.  In a fresh microcentrifuge tube, the suspended phage were re-precipitated with 
polyethylene glycol/NaCl on ice for 60 min.  The precipitate was then spun again at 
10,000 rpm for 10 min at 4°C and the supernatant was discarded.  The phage-containing 
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pellet was re-suspended in Tris-buffered saline and spun again for 1 min to remove 
residual polyethylene glycol.  The cleared phage-containing supernatant was transferred 
to a fresh tube and stored at 4°C.   
Amplified phage were titered and diluted in PBS/BSA+T to ~1011 PFU/mL for 
subsequent rounds of panning.  After four rounds of panning, individual plaques from the 
final round were isolated and incubated overnight in LB broth containing a 1:100 dilution 
of an overnight culture of E. coli ER2738, at 37°C with gentle agitation.  Phage DNA 
was isolated from overnight cultures using the S.N.A.P. MiniPrep kit (Thermo-Fisher 
Scientific) and sequenced using a -96gIII sequencing primer in order to identify the 
peptides displayed on the N-terminal portions of the pIII coat protein, presumably 
responsible for GlyR binding. 
3.2.4- Two-electrode voltage-clamp electrophysiology 
Oocyte isolation, injection, and electrophysiological recordings were performed 
as described in chapter 2 with the following modifications:  All solutions were prepared 
in MBS or MBS + 2.5 mM tricine.  Peptides were diluted in MBS or MBS + 2.5 mM 
tricine to final working concentrations from frozen 10 mM stocks.  When maximally-
effective concentrations of agonists were applied, applications lasted for 15 sec and were 
followed by 10-15 min washouts with MBS to allow for receptor re-sensitization.  For 
experiments using submaximal concentrations, glycine concentrations that yielded 5-10% 
of the maximally-effective glycine response (EC5-10) were applied for 45 sec followed by 
3-5 min washouts with MBS to allow for receptor re-sensitization.  Peptides were co-
applied with agonist following a 45 sec pre-incubation of peptide alone.   
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3.2.5- Determination of Zinc Concentration in Peptide Stocks 
Zinc concentrations in peptide stocks were determined using a quadrupole-based 
Agilent 7500ce inductively-coupled plasma mass spectrometer (ICP-MS) at the Jackson 
School of Geosciences Isotope Geochemistry Facility at the University of Texas at 
Austin.  10 mM stocks of peptide were diluted 10-fold in 2% HNO3 before analysis.  




3.3.1- Selection of 1glycine receptor-binding peptides 
Phage display was conducted using the Ph.D.-7 Phage Display Library from New 
England Biolabs containing approximately 109 unique heptapeptide sequences displayed 
pentavalently on M13 phage.  In an attempt to obtain peptides selective for the  GlyR 
subtype, we employed a modified version of our previous phage display procedure (Tipps 
et al., 2010) in which the phage library was first subjected to a subtractive panning step 
against -expressing (D7.1), or- and -expressing (D7.2) HEK 293 cells.  In 
total, 40 peptides were identified via phage display as capable of binding to the  




Table 3.1: List of peptide sequences identified after panning with the Ph.D-7 library. 
D7.1 phage: positive selection = 1 GlyR, negative selection = 2 GlyR.  D7.2 phage: 
positive selection = 1 GlyR, negative selection = 2 and 3GlyR.  Peptides in bold 
are those that enhance 1 GlyR function by ≥20% potentiation of EC5-10 glycine 
mediated currents. 
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3.3.2- Electrophysiological characterization of  glycine receptor-binding 
peptides 
Of the 40 peptide sequences initially identified, 25 were synthesized and 
characterized for their actions on  GlyRs via two-electrode voltage clamp 
electrophysiology in Xenopus laevis oocytes.  Peptides were tested at 30 M, a 
concentration previously shown to be sufficient to affect GlyR function (Tipps et al., 
2010).  A glycine concentration that yielded 5 to 10 percent of the maximally-effective 
glycine response (EC5-10) was initially identified in each oocyte and applied several times 
for 45 sec, followed by 3-5 min washouts to allow for receptor re-sensitization.  Peptide 
was applied for 30 sec alone followed by a 45 sec co-application with EC5-10 glycine.  
Peptide applications resulted in a range of effects from 26.8 ± 4.9% inhibition (D7.1-115) 
to 93.3 ± 12.2% potentiation (D7.2-123) of the EC5-10 glycine response (Fig. 3.1).  None 
of the peptides had effects in the absence of glycine, implying that they lack both GlyR 
agonist activity as well as effects at any endogenous oocyte proteins that could influence 
the holding current of the oocyte.  During the course of conducting experiments, we 
sometimes noticed variations in the degrees of modulation produced by peptides 
synthesized in different batches (Fig. 3.2).  This was not entirely unexpected as net-
peptide content can vary between batches of synthetic peptides and peptide 
concentrations were calculated based on the dry weight of the lyophilized powder 
provided by the supplier.  In order to prevent batch-to-batch variations from confounding 
results in characterization experiments, all data presented below were obtained from 




Figure 3.1: Screen for peptide activity at the  glycine receptor 
(A) Sample two-electrode voltage-clamp tracing of the effects of 30 M D7.1-115 on 
 GlyRs activated by EC5-10 glycine.  (B) Sample tracing of the effects of 30M D7.1-
122 on  receptors activated by EC5-10 glycine.  (C) The percent change in EC5-10 
glycine responses produced by 30 M concentrations of peptides that were pre-incubated 
for 30 sec followed by a 45 sec co-application with EC5-10 glycine.  Peptides exhibited 
varying degrees of activity at the  GlyR, but none had an effect in the absence of 
glycine.  Data are expressed as the mean ± S.E.M. across all batches of peptides tested on 





Figure 3.2:  Batch-to-batch variation of peptide modulation of the  glycine 
receptor.   
Four peptides were synthesized multiple times to acquire enough material for 
characterization experiments.  The different batches displayed varying degrees of activity 
on  GlyRs when 30 M concentrations of peptides, calculated based on dry peptide 
weight, were pre-incubated for 30 sec followed by a 45 sec co-applications with EC5-10 
glycine.  This is likely due to varying net peptide content between batches.  Data are 
expressed as the mean ± S.E.M. of 3-7 oocytes obtained from at least two frogs. 
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To determine if peptides were capable of affecting GlyR-mediated currents at 
lower concentrations, six different peptides of the initial screen were applied at 1, 3, 10, 
and 30 M concentrations to  GlyRs activated by EC5-10 glycine.  The threshold 
concentrations of activity for the three most efficacious of these peptides were between 3 
and 10 M (Fig. 3.3).  Previous work in our lab illustrated the abilities of allosteric 
modulators to differentially affect currents produced by saturating concentrations of 
agonists varying in efficacy (Kirson et al., 2012, 2013).  In order to test if this was also 
true for peptide modulation, 30 M D7.2-122 was tested for its ability to modulate  
GlyRs activated by maximally-effective concentrations of the partial agonist taurine and 
the higher efficacy agonist glycine (Fig. 3.4).  As with other allosteric modulators, D7.2-
122 had no effects on currents produced by saturating glycine concentrations but did 
enhance currents produced by a saturating concentration of taurine. 
In order to determine whether negative selection during phage panning against 
GlyRs of different subunit composition allows for the identification of peptides with 
subunit selectivity, the most effective peptides were applied to , , and  GlyRs 
activated by EC5-10 glycine (Fig. 3.5).  Interestingly, all peptides had higher activity on 
 and  receptors compared to F(2,44) = 4.24, P <0.025; Two-way ANOVA].  
However, peptides appeared to be equally or slightly more effective in enhancing  
than  GlyR function, despite inclusion of the  receptor subunits in the D7.2 







Figure 3.3: Concentration dependence of the two most effective glycine receptor 
enhancing peptides.   
The percent change in EC5-10 glycine currents produced by 1, 3, 10, and 30 M 
concentrations of peptides pre-incubated for 30 sec followed by 45 sec co-applications 
with EC5-10 glycine.  Data are represented as the mean ± S.E.M. of 3-5 oocytes obtained 
from at least 2 frogs.  
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Figure 3.4:  Peptide activity on  glycine receptors activated by maximally-
effective agonist concentrations 
 (A) Sample tracings showing the effects of 30 M D7.2-122-A on a saturating 
concentration of the high efficacy agonist glycine and (B) the partial agonist taurine.  
Peptide was pre-incubated 30 sec followed by a 45 sec co-application with saturating 
agonist concentrations. (C) Summary of the effects of 30 M D7.2-122-A on  
receptor currents generated by maximally effective concentrations of glycine or taurine.  
Peptide D7.2-122-A had no effect on currents generated by saturating glycine 
concentrations while enhancing currents generated by saturating taurine concentrations.  
Data are represented as the mean ± S.E.M. of 3 oocytes obtained from two frogs.  
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Figure 3.5: Subunit specificity of select peptides.   
Percent change in EC5-10 glycine responses on , , and  GlyRs produced by 30 
sec pre-incubations of 30 M concentrations of peptides followed by 45 sec co-
applications with EC5-10 glycine.  All peptides had greater effects on  and , 
compared to  GlyRs.  Activity at  receptors was the same or slightly increased 
for all peptides relative to  despite inclusion of  subunits in the negative selection 
step of the D7.2 panning series.  Data are expressed as the mean ± S.E.M. of 3-6 oocytes 






3.3.3- Identification of possible consensus sequences for glycine receptor-
enhancing peptides 
While there is no obvious amino acid consensus sequence among all of the 40 
peptides identified by phage panning, analysis of their amino acid compositions revealed 
selection both for and against particular amino acids within the identified peptides, 
compared to the observed frequencies of amino acids within the library as a whole, as 
characterized by the manufacturer (Fig. 3.6A,B).  Fig. 3.6A shows the observed 
frequencies of individual amino acids expressed as the percentage of all 280 amino acids 
present within the 40 identified heptapeptides, while Fig. 3.6B expresses the percent 
change in the observation frequency of amino acids in the 40 identified peptides 
compared to the observed frequency of amino acids in the whole library, as characterized 
by New England Biolabs.  Overall, it is clear that amino acids T, P, and G were strongly 
selected for while K, W, F, E were selected against (≥30% increase or decrease in 
observed frequency, respectively).  A more striking selection is seen when analyzing the 
amino acid compositions of only the eight GlyR-enhancing peptides that produced ≥20% 
potentiation of EC5-10 glycine responses (Table 3.1, bold; Fig. 3.6C,D).  Here T, P, S, D, 
Q, and W are all strongly selected for (≥45% increase in observed frequency) while L, N, 









Figure 3.6: Selection for specific amino acids during phage display panning.   
(A)  The observed frequencies of individual amino acids expressed as the percent of all 
280 amino acids within the 40 peptides identified in panning series D7.1 and D7.2.  (B)  
The percent change in observation frequency of amino acids in the 40 identified peptides 
compared to the observed frequency of amino acids in the library as a whole.  (C)  The 
observed frequency of individual amino acids expressed as the percent of all 56 amino 
acids within the eight GlyR-enhancing peptides (those that produce ≥20% potentiation of 
EC5-10 glycine mediated currents).  (D)  The percent change in observation frequency of 
amino acids in the 8 receptor enhancing peptides compared to the observed frequency of 
amino acids in the library as a whole.  Observation frequency of amino acids in the 






























Table 3.2:  Possible consensus motifs for  GlyR enhancing peptides (those that 
produce ≥20% potentiation of EC5-10 glycine mediated currents). 
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Further analysis of the positions of the amino acids that were strongly selected for 
in the eight GlyR-enhancing peptides revealed several possible consensus sequences that 
may contribute to their enhancing abilities (Table 3.2).  First, serines are present towards 
the C-terminal regions of peptides, at positions 6 or 7 in six of eight enhancers.  Further, 
four out of eight peptides contain the sequence PxxS and in the two most effective 
peptides, D7.2-122 and D7.2-123, this sequence is expanded to TxPxxS, where 'x' could 
be any amino acid.  The two peptides that do not contain serines at the C-terminal region 
(D7.1-107 and D7.2-111) contain the consensus xxxQxPx.  In addition, D7.1-107, D7.1-
118, and D7.2-123 all contain TxT while D7.2-122 and D7.2-123 both contain TTxxxxx 
as well as sharing the sequence TxPxxS.  In order to determine if consensus data could be 
used in the design of custom GlyR-enhancing peptides, we generated a synthetic peptide 
combining the TTxxxxx and TxPxxS motifs of D7.2-122 and D7.2-123.  This custom 
peptide, denoted Con-1, had the sequence TTAPAAS and enhanced  GlyR function 













Figure 3.7: Concentration-dependent enhancement of  GlyR function by 
custom designed peptide. 
Peptide Con-1 (TTAPAAS) was designed through the combination of the consensus 
sequences found in the two most effective GlyR-enhancing peptides.  Con-1 enhanced 
Cglycine currents in a concentration dependent manner, validating the use of the 
consensus sequence data in the development of custom GlyR-enhancing peptides.  







3.3.4- Characterizing the role of zinc in peptide action 
Zinc affects modulation of the GlyR by ethanol, with zinc chelation markedly 
decreasing alcohol enhancement of receptor function when tested using submaximal 
glycine concentrations (McCracken et al., 2010).  In order to determine what role, if any, 
zinc plays in the activities of these peptides at the GlyR, potentiating concentrations of 
select peptides were co-applied with the zinc-chelating agent tricine.  As seen in Fig. 3.8, 
removal of zinc by tricine almost completely abolishes modulation by all peptides except 
D7.2-123.  Interestingly, the inhibitory action of D7.1-115 was also blocked in the 
presence of tricine, implying a possible zinc-dependence of peptide action.  Moreover, 
zinc is a known contaminant in many biological buffers and labware at concentrations 
capable of affecting GlyR function (Cornelison and Mihic, 2014; Kay, 2004).  To ensure 
that the variable effects of the different peptides we tested were not due to varying levels 
of zinc contamination within the peptides themselves, samples of a variety of peptides 
were submitted for ICP-MS analysis to quantify total zinc content.  Fig. 3.9 compares 
peptide effects on EC5-10 glycine-mediated currents relative to zinc concentrations 





Figure 3.8: Zinc chelation by tricine inhibits the effects of peptides at  glycine 
receptors.    
The percent change in EC5-10 glycine responses produced by peptides that were pre-
incubated for 30 sec followed by a 45 sec co-application with EC5-10 glycine in MBS or 
MBS + 2.5 mM tricine.  All peptides were applied at a concentration of 100 M except 
D7.2-111-A and D7.2-123-B which were applied at 30 M.  Zinc chelation by tricine 
blocked or strongly inhibited the effects of all peptides tested.  Data are expressed as the 
mean ± S.E.M. of 3-4 oocytes obtained from at least two frogs. 
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Figure 3.9: Correlation between peptide activity on  receptors and zinc 
contamination as determined by ICP-MS of peptide solutions.   
Aliquots of the same batch of peptide were used for the determination of GlyR 
modulation, via two-electrode voltage clamp, and quantitation of total zinc content in 
peptide stock by ICP-MS.  Electrophysiological and ICP-MS data represent the values for 
30 M peptide except where noted, when multiple concentrations were tested.  The 





The GlyR is a putative target for the treatment of inflammatory pain and 
alcoholism (Blednov et al., 2015; Molander et al., 2007, 2005; Molander and Söderpalm, 
2005a; Tipps et al., 2010; Xiong et al., 2012) and novel specific modulators of GlyR 
function could thus have potential therapeutic applications.  Of particular interest would 
be modulators capable of enhancing receptor activity, as several studies have shown that 
GlyR activation in the nucleus accumbens and ventral tegmental area decreases ethanol 
drinking in rodents (Molander and Soderpalm, 2005a; Molander et al., 2005; Li et al. 
2012).  Tipps et al. (2010) demonstrated the feasibility of utilizing phage display to 
identify novel peptide modulators of the GlyR.  I expanded on these studies, identifying 
heptapeptides acting on the GlyR with subunit selectivity (Figs. 3.1 & 3.5), and 
characterizing peptide actions on receptor function.  To achieve this, I incorporated a 
negative selection step into the phage selection process, in which the phage library was 
first washed over HEK 293 cells expressing GlyR subunits we wished to select against 
before panning against the GlyR target of interest.  Peptides that bound non-specifically 
to the endogenous membrane components of HEK 293 cells, or to our expressed negative 
selection receptor subunits would, in principle, be eliminated from the population of the 
library upon transfer of the supernatant to the positive selection plates containing HEK 
293 cells expressing the  GlyR.  Through this negative selection step peptides 
capable of acting selectively on compared to  GlyRs were identified.  However, 
we did not identify peptides that differentiated between and  GlyRs (Fig. 3.5) 
despite the inclusion of the latter in the negative selection procedure of panning series 
D7.2.  This may be due to a higher level of similarity between 1- and 3-containing 
GlyRs at the peptide binding areas.  Why then did any -binding peptides survive the 
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panning procedure if they were negatively selected against?  One reason could be that the 
panning is somewhat 'leaky'.  If some phage capable of binding in the negative selection 
do not bind, but do bind in the subsequent positive selection, they would be amplified and 
re-introduced into the next round of panning.    
For molecules with potential for therapeutic use, high potency is desired, 
preferably in the nM or lower concentration range.  However, the GlyR-specific peptides 
identified using the New England Biolabs Ph.D. libraries, both in this study (Fig. 3.3) and 
by Tipps et al. (2010), acted at low M concentrations.  This could be due to the 
pentavalent display of these libraries.  Multivalent display can lead to an avidity effect 
where phage displaying multiple copies of a particular peptide, each binding to the target, 
increase the apparent affinities of the multivalent phage-peptide fusions, compared to 
when peptides are tested alone.  This phenomenon has been well documented in the 
phage display literature (Lowman, 1997).  In order to overcome this, one can utilize a 
monovalent display system, such a phagemid display system, when performing panning 
procedures (Lowman, 1997; Qi et al., 2012).  Alternatively, peptide potency could be 
increased through affinity maturation by using the sequence of the most promising 
peptides from initial screens, such as D7.2-122 or D7.2-123 in this case, as a scaffold for 
the creation of a new phage library in which all displayed peptides would be some 
variation of the originally-identified sequences.  We are investigating both possible 
methods to identify peptides that act with greater potency at the GlyR.  
The variety of amino acid sequences seen in the 40 identified peptides (Table 3.1) 
reflects the large and diverse nature of the pentameric GlyR, as it is likely that such a 
large molecular structure presents many potential binding sites for the various peptides 
contained within the library.  Further, it should be noted that phage display can only 
identify peptides capable of interacting with a particular target, and does not provide 
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information about any possible functional effect of the peptides at that target.  Therefore, 
we narrowed our consensus search to only the eight peptides that enhanced EC5-10 
receptor currents ≥20% and revealed several possible amino acid consensus sequences 
that may contribute to their abilities to positively modulate GlyR function (Table 3.2). 
The most prevalent consensus was the sequence PxxS, found in four of eight peptides, 
where the proline residue is located at either positions 3 or 4 and the serine is located at 
the C-terminal positions 6 or 7.  Further, this consensus is expanded within the top two 
enhancing peptides, D7.2-122 and D7.2-123, to TxPxxS.  These two peptides also both 
contained TTxxxxx, which may also be responsible for their robust abilities to enhance 
GlyR function.  In addition to these sequences, we found that three of eight allosteric 
enhancers contained the sequence TxT, and two contained xxxQxPx.  Of the 17 of 25 
characterized peptides that did not enhance receptor function ≥20%, TxT was found in 
three (D7.1-104, D7.1-112, and D7.2-015), QxP was found in one (D7.2-120) and PxxS 
was found in one (D7.1-110).  It may be that these three consensus sequences allow for 
interaction with the GlyR, and enhancing activity relies on the presence of other specific 
sequences within the peptide; alternatively, other amino acids within these peptides may 
interfere with the GlyR-enhancing activity that these consensus sequences contribute.  
Further, it is possible that these peptides could enhance receptor activity at higher 
concentrations, but are less potent than the eight that did.   
We next asked whether consensus data could be used in the design of custom 
GlyR-enhancing peptides.  In order to maximize the probability of success, we combined 
the consensus sequences that were shared by the two most effective GlyR-enhancing 
peptides, D7.2-122 and D7.2-123.  The resultant peptide, denoted Con-1, had the 
sequence TTAPAAS and was capable of enhancing  GlyR function in a 
concentration dependent manner with approximately 40% enhancement by 30 M 
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peptide (Fig. 3.7).   This demonstrates the utility of using the consensus sequences 
reported here as a starting point in the future design of higher potency peptides.  One 
potential method for such studies could be the creation of a novel phage display library in 
which each clone displays a variant of the Con-1 sequence, replacing the alanine residues 
with a variety of different amino acids.  This type of phage display based affinity 
maturation could allow for the identification of complementary residues that increase the 
ability of the core consensus sequence to enhance GlyR function. 
Zinc is a biphasic modulator of the GlyR, capable of enhancing receptor function 
at concentrations below approximately 10 µM, and inhibiting it at higher concentrations 
(Bloomenthal et al., 1994; Harvey et al., 1999; Laube et al., 1995).  It is clear that some 
peptides, such as D7.2-123-B, contain sufficient contaminating zinc to affect GlyR 
function.  However, ICP-MS measures total zinc, and there is no way to tell how much of 
this value reflects free zinc concentrations acting at the GlyR.  Further, the relationship 
between the degree of receptor modulation observed and zinc concentration of the 
various peptides indicates that peptide effects cannot solely be due to contaminating zinc 
(Fig. 3.9). For example, peptides that range in activity between -24.19% to 46.60% 
change in EC5-10 glycine responses contain between 12.38 - 15.36 nM zinc, a very small 
range that could not account for the degree of variance observed in the peptide effects.  
Further, D7.2-123-B had very similar effects at 30 and 100 M concentrations, despite 
there being over a 3-fold difference in zinc concentration (108.68 vs. 362.38 nM zinc) in 
those two peptide preparations.  GlyR potentiation by zinc typically peaks around 1 M 
zinc (Miller et al., 2005), with significantly different effects between 100 and 300 nM 
zinc.  Therefore, the similarity in effects between the different concentrations of D7.2-
123-B must be due to some interaction between both zinc and peptide effects at the GlyR.   
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Previous studies have shown that zinc interacts with other allosteric modulators at 
the GlyR (Kirson et al., 2013; McCracken et al., 2010, 2013a,b).  Of particular note, is 
that the chelation of zinc via tricine decreases the effects of alcohol at 1-, 2-, and 3-
containing GlyRs, essentially blocking the actions of ethanol at concentrations producing 
under 100% potentiation of EC5-10 glycine currents (≤100 mM ethanol), while 
significantly inhibiting alcohol effects at higher concentrations (200 mM ethanol) 
(McCracken et al., 2010, 2013a,b).  It is possible that zinc acts as a co-factor necessary to 
observe appreciable modulation of receptor function by allosteric modulators at 
concentrations that produce little effect on their own.  Nanomolar concentrations of zinc 
sufficient to enhance GlyR function are ubiquitous in vivo and in vitro, and the receptor 
may have evolved to respond optimally to glycine when zinc is bound.  Thus it is 
probable that peptide selection occurs to zinc-bound GlyRs during the panning procedure. 
Regardless, free or rapidly-exchangeable forms of zinc are maintained in the brain at 
levels capable of potentiating receptor currents, indicating that zinc dependence would 
not necessarily hinder the potential use of these peptides in vivo (Frederickson et al., 
2006b; Frederickson and Bush, 2001).   
In summary, we have extended our initial observations demonstrating the utility 
of using a modified phage display procedure in the discovery of novel allosteric 
modulators of the GlyR.  Expression of target channels in HEK 293 cells ensured the 
proper conformation of multimeric channels for phage display libraries to be panned 
against, yielding numerous heptapeptide sequences.  The addition of a negative selection 
step in which libraries are first washed over cells expressing receptors similar to the 
target can help in obtaining peptides with subunit selectivity, but may require a more 
stringent selection if the targets are molecularly similar.  Additionally, the zinc-
dependence of peptide activity seen here (Fig. 3.8), taken together with previous 
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observations of the zinc-dependence of ethanol actions on the GlyR, indicates a possible 
function of zinc as an endogenous co-modulator necessary for efficient allosteric 




Chapter 4: Validating the use of mutant glycine receptors for 
studying interactions between allosteric modulators and zinc 
4.1- Introduction 
A variety of agents act as positive allosteric modulators of GlyR function, 
including ethanol, volatile anesthetics, and inhaled drugs of abuse (Mihic et al., 1997; 
Beckstead et al., 2000; Welsh et al., 2010).  In addition to these exogenous compounds, 
GlyRs are also modulated by endogenous agents such as the divalent metal cation zinc 
(Bloomenthal et al., 1994; Laube et al., 1995).  Rapidly-exchangeable zinc (referred to as 
“free” zinc) is ubiquitous in the central nervous system, found both tonically at 
nanomolar concentrations in cerebrospinal fluid (CSF) (Frederickson et al., 2006b) and 
released phasically from zinc-containing synapses, resulting in higher local 
concentrations (Frederickson et al., 2006a; Qian and Noebels, 2005; Vogt et al., 2000).  
Zinc biphasically modulates GlyR function, enhancing currents at concentrations below 
~10M while inhibiting GlyR function at higher concentrations (Bloomenthal et al., 
1994; Laube et al., 1995).  This is thought to be the result of at least two distinct zinc-
binding sites on the receptor, a high affinity GlyR-enhancing site, and a low affinity 
inhibitory site (Harvey et al., 1999; Millet et al., 2005; Nevin et al., 2003).  While tonic 
free zinc is found at concentrations on the lower end of the GlyR-enhancing range 
(Frederickson et al., 2006b), the concentrations of zinc released synaptically are still 
somewhat controversial.  Many studies report that local zinc concentrations remain 
within the GlyR-enhancing range (<10M) after synaptic release, while other studies 
have measured concentrations of up to 100 M zinc (Frederickson et al., 2006a; Qian and 
Noebels, 2005; Vogt et al., 2000).   
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In addition to being present in vivo, zinc is a contaminant commonly found in 
many types of labware and reagents at nanomolar concentrations capable of affecting 
GlyR function (Cornelison and Mihic, 2014; Kay, 2004).  Additionally, chelation of 
contaminating zinc significantly decreases GlyR enhancement by a variety of modulators, 
including ethanol (McCracken et al., 2010, 2013a,b) and recently-discovered synthetic 
peptides (See chapter 3; Cornelison et al., 2016).  However, the mechanism by which 
zinc interacts with these other allosteric modulators at the GlyR is currently unknown.  
Further, these studies have relied on the use of relatively high (2.5 - 10 mM) 
concentrations of the zinc-chelator tricine that could conceivably affect channel or 
modulator function in ways apart from its ability to chelate zinc.  For example, it is 
possible that tricine could act itself as a negative allosteric modulator of GlyR function 
and that the reduction in GlyR currents seen in the presence of tricine could be due to this 
effect in addition to chelation of zinc.  Additionally, the strong hydrogen bonding 
potential of tricine could effectively “chelate” hydrophilic allosteric modulators of the 
GlyR, such as ethanol, thereby seemingly decreasing their effects.   Further, tricine’s high 
ionic strength could conceivable alter peptide conformation, thereby accounting for the 
tricine-mediated inhibition of peptide modulation seen in chapter 3.   
Several single point mutations of the 1 GlyR have been reported to confer 
insensitivity to enhancement by zinc, including substitutions of the aspartic acid residue 
at position 80 to alanine (D80A) (Hirzel et al., 2006; Lynch et al., 1998; McCracken et 
al., 2013a) or glycine (D80G) (Laube et al., 2000), as well as the mutation of tryptophan 
at position 170 to serine (W170S) (Zhou et al., 2013).  In this chapter we investigate the 
utility of these “zinc-insensitive” GlyR mutants as an alternative method to zinc chelation 
for the study of GlyR modulation in the absence of co-modulation by zinc. 
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4.2- Materials and Methods 
4.2.1- Generation of point mutations 
The 1 D80A GlyR mutant cDNA was a gift from the lab of Dr. R. Adron Harris 
(McCracken et al., 2013a).  The 1 D80G and W170S point mutations were generated 
via site-directed mutagenesis with the QuickChange II mutagenesis kit (Agilent 
Technologies, Santa Clara, CA) and commercially engineered mutagenesis primers 
(Integrated DNA Technology, San Diego, CA) using wildtype 1 GlyR cDNA in a 
modified pBK-cytomegalovirus vector (Mihic et al., 1997) as a template.  Successful 
mutagenesis was verified via Sanger sequencing using AB 3730 and AB 3730XL DNA 
analyzers (Thermo-Fisher Scientific, Waltham, MA) at the University of Texas at Austin 
DNA Sequencing Facility.  The GlyR 1 cDNAs were completely sequenced to ensure 
the absence of any unwanted mutations. 
4.2.2- Two-electrode voltage-clamp electrophysiology 
Oocyte isolation, injection, and electrophysiological recordings were performed 
as described in chapter 2.  Glycine and modulators were diluted in, and all 
electrophysiological recordings were performed in, modified Barth’s saline (MBS) 
buffer.  For all experiments, modulators were pre-incubated for 30 sec prior to co-
application with glycine.  When maximally-effective concentrations of glycine were 
used, applications lasted for 10 sec and were followed by a 15 min (wildtype and W170s 
GlyRs) or 20 min (D80A and D80G GlyRs) washout to allow for full receptor re-
sensitization. When concentrations of glycine giving 5-10% of a maximally effective 
concentration of glycine (EC5-10) were used, applications lasted 45 sec followed by a 5 
minute washout. For all experiments using EC5-10 glycine, maximally effective glycine 
responses were determined and used to find the EC5-10 glycine.  This process was 
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repeated for each condition tested (i.e. MBS, MBS + 2.5 mM tricine).  Every EC5-10 
glycine + modulator co-application was flanked by an EC5-10 glycine control for 
comparison.  Maximally effective glycine responses were checked again at the end of 
every experiment to account for drift in glycine responses over time.  Applications in 
which control EC5-10 glycine responses drifted above EC10 or below EC5 were not used. 
For zinc concentration-response curves, the effects of 0.03-10 M ZnCl2 on EC5-10 
glycine currents were determined.  Washout durations after zinc co-application had to be 
increased from 5 min to 10-15 min when concentrations > 300 nM ZnCl2 were used in 
order to allow for complete zinc washout to occur and for return to baseline EC5-10 
currents.  For glycine concentration-response curves, 0.03-100 mM glycine (in MBS + 
2.5 mM tricine, with or without 2.5 M ZnCl2), were applied for 10-45 sec as required to 
reach stable peak currents.   
4.2.2 Data analysis 
Peak currents were measured and used in data analysis.  For each oocyte, currents 
observed in the presence of glycine plus modulators were compared with currents 
generated by glycine alone and expressed as the mean ± S.E.M of the percent change in 
glycine-mediated current.  Significant differences were determined using the Students t-
test, analysis of variance (ANOVA), two-way ANOVA, and Tukey post-hoc tests, as 
indicated.  All statistical testing was performed using SigmaPlot 11.0 (Systat Software, 
San Jose, CA).   
 57 
4.3- Results 
4.3.1- Characterization of 1 wildtype, D80A, D80G, and W170S GlyR 
sensitivity to enhancing concentrations of zinc.  
In order to verify previously-published data reporting that D80A, D80G, or 
W170S mutations of the 1 GlyR confer insensitivity to enhancing concentrations of 
zinc, mutant and wildtype homomeric receptors were expressed in Xenopus laevis 
oocytes.   The effects of 100 nM ZnCl2 and 2.5 mM of tricine were determined on 
currents generated by a concentration of an EC5-10 concentration of glycine.  Surprisingly, 
in addition to wildtype receptors, D80A and D80G GlyRs showed robust sensitivity to 
both contaminating and exogenously-added zinc (Fig. 4.1).   Figs. 4.1A and 4.1B show 
that tricine chelation of contaminating zinc, previously reported to measure around 45 
nM (Cornelison and Mihic, 2014), resulted in a similar decrease in EC5-10 glycine 
currents in wildtype, D80A, and D80G receptors while minimally affecting W170S 
GlyRs.  Figs. 4.1A and 4.1C show that the co-application of 100 nM ZnCl2 caused a 
similar enhancement of EC5-10 glycine currents in wildtype and D80A GlyRs that was 






Figure 4.1:  The effects of low nanomolar concentrations of zinc on 1 homomeric 
wildtype (WT), D80A, D80G, and W170S glycine receptors.   
(A) Sample tracings showing the effects of 100 nM ZnCl2 or 2.5 mM of the zinc-chelator 
tricine on EC5-10 glycine responses in WT or mutant 1 glycine receptors. (B) Summary 
graph of the effects of 2.5 mM tricine on EC5-10 glycine currents in WT and mutant 
glycine receptors.  Tricine had a significantly decreased effect on W170S compared to 
WT GlyRs.  Data are shown as the mean ± S.E.M. of 3-4 oocytes. One-way ANOVA 
followed by Tukey’s post-hoc: *, P < 0.05. (C) Summary graph of the effects of 100 nM 
ZnCl2 on EC5-10 glycine currents in WT and mutant GlyRs. 100 nM ZnCl2 had a 
significantly decreased effect on D80G and W170S compared to WT GlyRs.  Data are 
shown as the mean ± S.E.M of 9-16 oocytes obtained from at least two frogs. One-way 
ANOVA followed by Tukey’s post-hoc tests: *, P < 0.05. ***, P < 0.001. 
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Due to the unexpected findings of robust enhancement by low nanomolar 
concentrations of zinc in 1 GlyR D80 mutants that were previously reported as being 
zinc-insensitive, we performed a more complete characterization of zinc enhancement in 
both wildtype and mutant receptors.  We first examined zinc-sensitivity of EC5-10 glycine 
currents across a wide range of GlyR-enhancing concentrations.  Fig. 4.2 illustrates the 
difference in GlyR enhancement of wildtype, D80A, D80G, and W170S GlyR by co-
application of EC5-10 glycine with 30 nM to 10 M ZnCl2.  A two-way ANOVA revealed 
a significant effect of genotype [F(3,119) = 76.68, p < 0.001], a significant effect of zinc 
concentration [F(5,119) = 14.367, p < 0.001], and a significant interaction of genotype x 
zinc concentration [F(15,119) = 2.40, p < 0.01].  Wildtype, D80A, and D80G receptors 
displayed bimodal zinc-response curves where zinc-enhancement increased in a 
concentration-dependent manner until peak potentiation was reached at 1 M.  This was 
followed by a concentration-dependent decrease in zinc enhancement that reflects zinc 
binding to the low-affinity inhibitory sites, resulting in competition between zinc-
enhancement and inhibition.  Conversely, W170S GlyRs showed no zinc-enhancement 
from 30 nM to 1 M ZnCl2, with inhibition at higher concentrations, consistent with 
previous results (Zhou et al., 2013).  When comparing wildtype to D80 mutant GlyRs, all 
three receptors had similar levels of enhancement at the low and high ends of the curve.  
However, D80G GlyRs exhibited a shallower zinc concentration-response curve than 
wildtype receptors, with significantly decreased peak zinc enhancement (p < 0.05).  
D80A GlyRs appeared to have a steeper curve with higher peak zinc-enhancement, but 






Figure 4.2.: The effects of enhancing concentrations of ZnCl2 on 1 homomeric WT, 
D80A, D80G, and W170S glycine receptors activated by EC5-10 
glycine.   
Data are shown as the mean ± S.E.M. of 4-8 oocytes obtained from at least two frogs.  A 
two-way ANOVA showed a significant effect of genotype [F(3,119) = 76.68, p < 0.001], 
a significant effect of zinc concentration [F(5,119) = 14.367, P < 0.001], and a significant 
interaction between genotype and zinc concentration [F(15,119) = 2.402, p < 0.005].  
WT, D80A, and D80G GlyR show bimodal concentration response curves with peak 
enhancement at 1 M ZnCl2.  Tukey’s post-hoc tests revealed peak zinc enhancement 
was significantly decreased in D80G compared to WT GlyR (p < 0.05) and while peak 
enhancement appeared to be increased in D80A compared to WT GlyR, this was not 
significant (p = 0.12). W170S GlyR currents were unaffected by ZnCl2 up to 1 M and 




  We next investigated how zinc enhancement of receptor function changes with 
increasing agonist concentration.  We first generated glycine concentration-response 
curves in the presence of 2.5 mM tricine to account for the effects of contaminating zinc 
on agonist EC.  We then plotted glycine EC values (triangles, right ordinate) and 
potentiation of corresponding currents by application of 2.5 M ZnCl2 in the presence of 
2.5 mM tricine (circles, left ordinate) against glycine concentration (Fig. 4.3).  Zinc 
potentiation significantly decreased with increasing glycine concentration for wildtype, 
D80A, and D80G receptors while W170S GlyRs showed minimal zinc potentiation that 
did not vary with agonist concentration.  When zinc potentiation of wildtype and D80 
mutant GlyRs was plotted against glycine EC (Fig. 4.4), there appeared to be differences 
between wildtype and mutant GlyRs in the magnitude of zinc enhancement at lower 
glycine ECs (< EC40).  In an attempt to quantify this, we partitioned the data into zinc 
effects at low (EC0-20) and intermediate-low (EC20-40) glycine.  One-way ANOVAs 
revealed significant differences between genotype at both low [F(2,26) = 5.812, p < 0.01] 
and intermediate-low EC [F(2,9) = 5.886, p < 0.05].  Tukey multiple comparisons post-
hoc tests showed that compared to wildtype receptors, zinc-enhancement of D80G 
receptors was significantly decreased at intermediate-low (EC20-40) glycine (+38.70 ± 









Figure 4.3:  Zinc enhancement of wildtype and mutant receptors across agonist 
concentration response curves. 
 Zinc sensitivity of (A) WT, (B) D80A, (C) D80G, and (D) W170S glycine receptors was 
measured across different agonist concentrations. Glycine concentration response curves 
were determined (triangles) in the presence of 2.5 mM tricine and ordinate values are 
shown on the right axis.  At each glycine concentration tested, the percent enhancement 
produced by 2.5 M ZnCl2 (in the presence of 2.5 mM tricine) was also determined 
(circles) and ordinate values are shown on the left axis.  The dotted line corresponds to 
0% zinc enhancement for reference.  One-way ANOVAs showed that enhancement by 
ZnCl2 decreased with increasing glycine concentration for WT [F(5,30) = 15.435, p < 
0.001, n = 5-7 ], D80A [F(5,21) = 24.153, p < 0.001, n = 4-5], and D80G [F(7,31) = 
7.785, p < 0.001, n = 4-7], but not W170S [F(6,28) = 0.472, p = 0.823, n = 3-6] GlyRs.  
Data are shown as the mean ± S.E.M. of the indicated number of oocytes obtained from 
at least two frogs. 
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Figure 4.4:  Zinc enhancement of WT and D80 mutant GlyRs as a function of 
glycine EC.  
Zinc-enhancement of WT (grey diamonds), D80A (black circles), and D80G (white 
circles) GlyRs plotted against glycine EC.  One-way ANOVAs revealed significant 
differences between genotypes at both EC0-20 glycine [F(2,26) = 5.812, p < 0.01] and 
EC20-40 glycine [F(2,9) = 5.886, p < 0.05].  Tukey multiple comparisons post-hoc tests 
showed that compared to WT receptors, zinc-enhancement of D80G receptors was 
significantly decreased at intermediate-low (EC20-40) glycine (+38.70 ± 11.64% change 
for D80G compared to +92.07 ± 8.91% change for WT, p < 0.01), but not EC0-20 glycine, 
suggesting a steeper decline in zinc mediated enhancement of D80G GlyRs with 




4.3.2- Effects of zinc chelation on ethanol enhancement of wildtype and 
W170S GlyRs. 
We next determined the effects of ethanol on W170S compared to wildtype 
GlyRs in the presence and absence of low nanomolar concentrations of zinc.  To do this 
we measured ethanol enhancement of EC5-10
 glycine currents for both wildtype and 
W170S receptors in normal MBS buffer (containing low nanomolar concentrations of 
contaminating zinc) and in buffer where contaminating zinc was chelated by tricine (Fig. 
4.5).   Consistent with McCracken et al. (2010), zinc-chelation by tricine significantly 
reduced enhancement of EC5-10 glycine currents by 50 and 200 mM ethanol in wildtype 
GlyRs.  W170S GlyRs showed significantly decreased EtOH modulation compared to 
wildtype receptors in standard MBS and this was not further decreased by tricine.  
Additionally, there was no difference between the magnitudes of EtOH enhancement of 
wildtype and W170S GlyRs in the presence of tricine.  Taken together, these data support 
the idea that the 1 W170S GlyR allows for the study of allosteric modulation of GlyRs 











Figure 4.5:  Effects of zinc chelation on ethanol enhancement of wildtype and 
W170S GlyRs  
(A) Sample tracings showing the effects of zinc chelation on EtOH modulation of GlyRs 
activated by EC5-10 glycine. The effects of 50 and 200 mM EtOH on EC5-10 glycine 
currents were first determined in standard MBS, known to contain low nM concentrations 
of contaminating zinc, and then determined in MBS containing 2.5 mM of the zinc-
chelator tricine. (B) Summary graph of the data presented in A.  Zinc chelation 
significantly decreased the effects of 50 and 200 mM EtOH in WT GlyRs. Ethanol 
enhancement of W170S GlyRs in normal MBS was decreased compared to wildtype 
receptors and was not further decreased by the addition of tricine.  There was also no 
difference in EtOH modulation between WT and W170S glycine receptors in the 
presence of tricine, indicating the W170S mutation allows for accurate depiction of 
allosteric modulation in the absence of co-modulation by zinc.  Data are shown as the 
mean ± S.E.M. of 4-7 oocytes obtained from at least two frogs.  Two-way ANOVA 
followed by Tukey’s post-hoc tests: **, P < 0.01.  ***, P < 0.001. 
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4.4- Discussion 
Apart from the ability of nanomolar concentrations of zinc to allosterically 
enhance GlyR function, low concentrations of zinc also interact with other allosteric 
GlyR modulators, such as ethanol, yielding effects greater than those produced by zinc or 
modulator applied alone (Cornelison et al., 2016; McCracken et al., 2010, 2013a,b).  We 
generally account for this phenomenon via the removal of “free zinc” from our buffers by 
the addition of chelating agents such as tricine.  However, these data did not discount the 
possibility that the addition of chelating agents such as tricine might have effects on 
receptor activation or allosteric modulation by means distinct from their abilities to 
chelate zinc.  Testing for the effects of allosteric modulators on GlyR mutants resistant to 
the enhancing properties of zinc would alleviate this concern.  We first attempted to use 
homomeric 1 D80A and D80G mutant GlyRs that were previously reported to be 
insensitive to the enhancing effects of zinc (Hirzel et al., 2006; Laube et al., 2000; Lynch 
et al., 1998; McCracken et al., 2013a).  However, our data revealed that these two 
mutants are not truly insensitive to enhancing concentrations of zinc (Fig. 4.1).  We then 
screened the 1 W170S GlyR and found that both tricine and 100nM ZnCl2 had 
negligible effects on W170S GlyR currents (Fig. 4.1), confirming this mutant’s reported 
lack of zinc enhancement and showing that tricine does not act as a modulator of GlyRs 
beyond its ability to chelate zinc.  This result also served as a positive control, markedly 
contrasting with the findings made using the two D80 mutants. 
The discrepancies between our data and previously published reports on the zinc-
insensitive nature of 1 GlyR D80 mutants prompted a more thorough characterization of 
their sensitivities to enhancing concentrations of zinc.  We first tested for the effects of a 
variety of GlyR-enhancing zinc concentrations on submaximal glycine currents in WT 
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and mutant receptors (Fig. 4.2).  While WT and D80A receptors showed similar zinc 
responses across the concentrations tested, D80G receptors had a much shallower 
concentration-response curve with significantly lower peak enhancement.  We have 
previously determined that our electrophysiological buffers (MBS) contain approximately 
45 nM concentrations of contaminating zinc (Cornelison and Mihic, 2014), a 
concentration that is similar to that found tonically in CSF (Frederickson et al., 2006b).  
However, other studies have reported up to approximately 200-800 nM contaminating 
concentrations of zinc in various electrophysiological buffers, suggesting that this could 
be a significant confound in the many published studies in the GlyR field (Thio and 
Zhang, 2006; Wilkins and Smart, 2002; Zheng et al., 1998).  As contaminating zinc has 
not generally been taken into consideration, the higher levels of zinc contamination in 
buffers used for previous studies of D80G GlyRs may have masked the effects of the 
experimentally added zinc in mutant receptors while still noticeably enhancing WT 
receptors.  However this would not explain why we saw at least as great an effect of zinc 
in D80A as in WT 1 GlyRs (Fig. 4.2).  We next investigated GlyR sensitivity to zinc on 
currents generated by a variety of agonist concentrations.  Allosteric modulators of ligand 
gated ion channels typically show the greatest effects at low agonist concentrations, with 
a decrease in percent enhancement occurring with increasing agonist concentration 
(Farley and Mihic, 2015).  Since previous studies of 1 D80 mutant GlyRs typically 
assayed zinc-sensitivity using higher glycine concentrations than reported here (≥EC25), 
we hypothesized that perhaps D80 mutants might have a steeper decline in zinc-
enhancement with increasing agonist concentrations than WT receptors, thereby 
appearing insensitive to zinc at currents generated by higher effective concentrations of 
glycine.  We found that D80A, D80G, and WT receptors all showed a decrease in zinc 
enhancement with increasing agonist concentration (Fig. 4.3).  However, D80G receptors 
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had significantly reduced zinc potentiation compared to WT receptors when activated by 
glycine concentrations ranging from EC20-40 but not EC0-20 (Fig. 4.4).  These data suggest 
that a steeper decline in zinc-enhancement with increasing agonist concentration, coupled 
with the possible presence of higher levels of contaminating zinc than in our buffers, may 
account for previous reports of abolished zinc enhancement in D80G GlyRs.  Once again, 
this would not explain why D80A GlyRs show such marked zinc enhancement in our 
hands. 
The exact GlyR residues that are involved in the high affinity binding of zinc 
remain unclear.  Our data suggests that D80 is not part of a high affinity zinc-binding site, 
as robust enhancement of receptor function by zinc is seen in both D80A and D80G 
GlyRs expressed in Xenopus laevis oocytes.  Other studies of D80 GlyR mutants are also 
contradictory as to whether D80 is a zinc binding residue.  Lynch et al. (1998) found that 
1 M zinc significantly increased the apparent affinities of both glycine and taurine in 
[3H]-strychnine binding assays of D80A mutant receptors, consistent with a mechanism 
of positive allosteric modulation.  Functionally, however, they found that glycine-
mediated currents in D80A GlyRs were insensitive to enhancement by zinc while taurine-
mediated currents were still enhanced.  They concluded that instead of acting as a zinc-
binding site, D80 may instead be involved in allosterically linking zinc binding to 
channel gating.  While our results could possibly account for the apparent lack of zinc 
enhancement in previous reports of D80G GlyRs, we were unable to do the same for the 
D80A receptor.  One speculative possibility is that D80A mutations differentially affect 
zinc enhancement of receptors expressed in different cell types as previous studies 
characterizing D80A receptors were conducted in mammalian cells while we utilized 
Xenopus laevis oocytes.   
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Another putative high-affinity zinc binding site associated with GlyR 
enhancement involves residues E192 and D194 of the 1 subunit (Miller et al., 2005).  
W170 is in very close proximity to these residues and mutation of W170 to serine is 
thought to disrupt this binding pocket, thereby preventing enhancement by zinc (Zhou et 
al., 2013).  Since we were able to successfully confirm the zinc-insensitive nature of this 
mutant, we investigated its utility as a model for studying GlyR modulation in the 
absence of co-modulation by zinc.   We did this by testing the effects of ethanol and 
tricine on W170S GlyRs in comparison with the effects of tricine on ethanol modulation 
of WT receptors (Fig. 4.5).  W170S receptors had a significantly decreased response to 
ethanol compared to WT receptors in the presence of contaminating (low nM) 
concentrations of zinc and this ethanol effect was not further decreased by tricine.  
Additionally, the degree of ethanol enhancement of W170S GlyRs was similar to what 
was seen for WT receptors in the presence of tricine.  This suggests that tricine has no 
effect on ethanol modulation of GlyRs apart from its ability to chelate zinc and 
demonstrates that the W170S receptor serves as an appropriate model to investigate 
modulator function in the absence of co-modulation by zinc. 
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Chapter 5: Insights into zinc’s interactions with allosteric 
modulators of the glycine receptor 
5.1- Introduction 
As discussed previously, it is now evident that contaminating levels of zinc are 
capable of affecting the modulation of GlyR function by other compounds (See chapter 3; 
Cornelison et al., 2016; McCracken et al., 2010, 2013a,b).  Specifically, it appears that 
the presence of low nanomolar concentrations of zinc act synergistically with positive 
allosteric modulators, such as ethanol, to enhance receptor function.  However, previous 
studies characterizing allosteric modulation of the GlyR have seldom accounted for the 
presence of contaminating zinc, therefore limiting our knowledge as to the extent of this 
phenomenon.  In the previous chapter we validated the utility of using the zinc-
enhancement insensitive 1 W170S GlyR to study GlyR modulation in the absence of 
co-modulation by zinc.  In this chapter we utilize this mutant receptor to answer several 
open questions about zinc’s ability to interact with other modulators of GlyR function.   
 
5.2- Materials and Methods 
5.2.1- Two-electrode voltage-clamp electrophysiology 
Oocyte isolation, injection, and electrophysiological recordings were performed 
as described in chapter 2.  Glycine and modulators were diluted in, and all 
electrophysiological recordings were performed in, modified Barth’s saline (MBS) buffer 
or MBS + 10 M ZnCl2.  For all experiments, modulators were pre-incubated for 30 sec 
prior to co-application with glycine.  When maximally-effective concentrations of 
glycine were used, applications lasted for 10 sec and were followed by a 15 min washout 
to allow for full receptor re-sensitization. When EC5-10 concentrations of glycine were 
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used, applications lasted 45 sec followed by a 5 minute washout. For all experiments 
using EC5-10 glycine, maximally-effective glycine responses were first determined and 
used to find the EC5-10 glycine.  This process was repeated for each condition tested (i.e. 
MBS and MBS + 10 M ZnCl2).  Every EC5-10 glycine + modulator co-application was 
flanked by an EC5-10 glycine control for comparison.  Maximally-effective glycine 
responses were checked again at the end of every experiment to account for drift in 
glycine responses over time.  Applications in which control EC5-10 glycine responses 
drifted above EC10 or below EC5 were not used.  Loss of volatile compounds through 
tubing and evaporation from bath was previously measured (Beckstead et al., 2000; 
Mihic et al., 1994; Yamakura et al., 1999).  All concentrations reported are the bath 
concentrations to which the oocytes were exposed.  All data were collected from oocytes 
obtained from at least two different frogs.   
5.2.2- Data analysis 
Peak currents were measured and used in data analysis.  For each oocyte, currents 
observed in the presence of glycine plus modulators were compared with currents 
generated by glycine alone and expressed as the mean ± S.E.M of the percent change in 
glycine-mediated current.  Significant differences were determined using the Student’s t-
test, two-way ANOVA, and Tukey post-hoc tests, as indicated.  All statistical testing was 




5.3.1- Peptide modulation of wildtype and W170S GlyRs 
First, we verified the ability of D7.2-123-B to enhance GlyR function in a zinc-
independent manner.  This peptide was identified from a phage display screen targeting 
the  GlyR (see chapter 3).  However, we were unable to successfully express 
functional 1(W170S): receptors and therefore compared peptide enhancement of 
homomeric 1 wildtype and W170S receptors (Fig 5.1).  Co-application of 30 M D7.2-
123-B with EC5-10 glycine potentiated homomeric wildtype receptor currents by 132.0%, 
similar to what was seen in receptors (Fig 3.2), and potentiated W170S homomeric 










Figure 5.1: D7.2-123-B modulation of 1 homomeric wtildypte and W170S GlyRs 
Peptide D7.2-123-B, tested at a concentration of 30 M, conferred 132.0% enhancement 
in wildtype 1 GlyRs and 43.52% potentiation of EC5-10 glycine currents in 1 W170S 
mutant receptors. 
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5.3.2- Volatile anesthetic and inhalant sensitivity of wildtype and W170S 
GlyRs under low nanomolar zinc conditions. 
We next used W170S GlyRs to probe for the involvement of low nanomolar 
concentrations of zinc on GlyR enhancement by other drugs of abuse.  The enhancement 
of EC5-10 glycine currents in wildtype and W170S GlyRs produced by several volatile 
anesthetics and inhaled drugs of abuse was determined in standard MBS (containing low 
nanomolar zinc).  There were no differences in GlyR enhancement between WT and 
W170S receptors by approximately minimum alveolar concentrations (MAC) of the 
volatile anesthetics isoflurane, chloroform, or halothane (Fig. 5.26A).  The MAC 
represents an anesthetic's ED50 in humans.  On the other hand, the inhalants 1,1,1-
trichloroethane (TCE), toluene, and trichloroethylene (TCY) showed a significantly 
decreased ability to affect GlyR function in W170S compared to WT receptors (Fig. 
5.2B), suggesting an interaction between zinc and inhalants to enhance GlyR function. 
5.3.3- Allosteric modulator sensitivity in wildtype and W170S GlyRs under 
low micromolar zinc conditions. 
Previous studies investigating the interaction between zinc and other allosteric 
modulators at the GlyR have focused on zinc concentrations ≤ 1 M, in which only the 
high affinity GlyR-enhancing zinc binding site would be occupied.  However, 
synaptically released zinc may result in higher local concentrations which may occupy 
both the high affinity enhancing and low affinity inhibitory zinc binding sites.  We 
therefore measured the effects of exogenously-added 10 M ZnCl2 on the modulation of 
EC5-10 glycine currents in WT and W170S GlyRs by ethanol, (Fig. 5.3) TCE, and 
halothane (Fig. 5.4).  Figure 5.3A shows sample tracings of ethanol’s effects on EC5-10 
glycine currents from wildtype and W170S GlyRs in normal MBS and MBS + 10 M 
ZnCl2.  Enhancement of EC5-10 glycine currents by 50 and 200 mM ethanol were 
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significantly decreased in WT GlyRs when 10 M ZnCl2 was added to the buffer.  
However, ethanol modulation of W170S GlyRs compared to WT receptors was already 
significantly decreased in standard MBS and was not further affected by the addition of 
zinc.  Additionally, there were no significant differences between ethanol modulation of 
WT and W170S GlyRs in the presence of 10 M ZnCl2.  A similar pattern was seen for 
TCE, in which the addition of 10 M ZnCl2 significantly decreased TCE enhancement 
for WT but not W170S GlyRs, with no significant differences between WT and W170S 
receptors in MBS + 10 M ZnCl2. (Fig. 5.4).  There were no significant differences in 
halothane modulation of WT and W170S GlyRs, regardless of the concentration of zinc 




Figure 5.2:  Co-modulation by low nanomolar zinc affects allosteric modulation of 
glycine receptors by inhalants but not volatile anesthetics.   
(A)  Summary graph of the effects of approximately minimum alveolar concentrations of 
three volatile anesthetics on WT and W170S glycine receptors activated by EC5-10 
glycine.  No significant differences were seen. Data shown as the mean ± S.E.M. of 4-5 
oocytes obtained from at least two frogs.  (B)  Summary graph of the effects of inhalants 
on WT and W170S glycine receptors activated by EC5-10 glycine.  Data are shown as the 
mean ± S.E.M. of 5 oocytes obtained from at least two frogs. Student’s t-test *, P < 0.05. 
**, P < 0.01. 
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Figure 5.3:  Higher concentrations of zinc, which may be found after synaptic 
release, inhibit EtOH enhancement of 1 WT but not W170S GlyRs.  
(A) Sample tracings showing the effect of 10 M added ZnCl2 on EtOH modulation of 
1 WT and W170S GlyRs activated by EC5-10 glycine. The effects of 50 and 200 mM 
EtOH on EC5-10 glycine currents were first determined in standard MBS buffer, known to 
contain low nM concentrations of contaminating zinc, and then determined in MBS 
containing 10 M ZnCl2.  (B) Summary graph of the data presented in A.  The addition 
of 10 M ZnCl2 to the buffer significantly decreased the effects of 50 and 200 mM EtOH 
in WT GlyRs.  Ethanol enhancement of W170S GlyRs in normal MBS was decreased 
compared to wildtype receptors and was not further decreased by added ZnCl2.  There 
was also no difference in EtOH modulation between WT and W170S GlyRs in the 
presence of added ZnCl2. Data are shown as the mean ± S.E.M. of 5-6 oocytes obtained 
from at least two frogs. Two-way ANOVA followed by Tukey’s post-hoc tests: **, P < 
0.01.  ***, P < 0.001. 
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Figure 5.4:   Higher concentrations of zinc inhibit TCE but not halothane 
enhancement of 1 WT but not W170S GlyRs.   
The addition of 10 M ZnCl2 to the buffer significantly decreased the effects of 0.56 mM 
TCE in WT GlyRs.  TCE enhancement of W170S GlyRs in normal MBS was decreased 
compared to wildtype receptors and was not further decreased by the addition of ZnCl2.  
There was also no difference in TCE modulation between WT and W170S receptors in 
the presence of added ZnCl2.  There were no significant differences in halothane 
modulation of WT and W170S GlyRs in the presence or absence of added ZnCl2.  Data 
are shown as the mean ± S.E.M. of 4 oocytes obtained from at least two frogs.  Two-way 




In chapter 4 we investigated the utility of 1 W170S mutant GlyRs for the study 
of GlyR modulation in the absence of co-modulation by enhancing concentration of zinc.  
Nanomolar concentrations of zinc have been shown to synergistically enhance ethanol 
modulation of GlyR function (McCracken et al., 2010, 2013a,b).  Further, it appears that 
modulation of GlyR function by recently discovered peptides is zinc-dependent, as the 
chelation of contaminating zinc abolished their ability to affect channel function (See 
chapter 3; Cornelison et al., 2016).  Due to the ubiquitous nature of zinc in the CNS, it is 
important to account for its ability to affect other modulators of GlyR function in order to 
have a better understanding of how these compounds work in vivo.  We therefore utilized 
the W170S mutant GlyR to investigate a variety of open questions involving zinc’s 
interactions with other modulators at the GlyR. 
We first tested for the ability of D7.2-123-B to enhance W170S GlyR function. 
D7.2-123-B was one of the most potent peptides identified in chapter 3, but also 
contained a significant amount of contaminating zinc that could possibly account for its 
enhancing effects.  ICP-MS measurements revealed the presence of over 100 nM 
contaminating zinc at the peptide concentrations tested electrophysiologically.  However, 
ICP-MS analysis only measures total zinc, and not the concentration of free zinc that 
would be able to act on the receptor. Chelation of contaminating zinc with tricine 
significantly reduced D7.2-123-B potentiation of GlyR function, suggesting that either 
contaminating zinc is responsible for some of the observed peptide effects or that peptide 
action is zinc-dependent, similar to ethanol.  The fact that tricine also inhibited 
modulation produced by other peptides, containing minimal concentrations of 
contaminating zinc, suggests zinc-dependence of peptide action.  However, it is possible 
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that the presence of such a high concentration of tricine (2.5 mM) could affect peptide 
modulation in a manner independent of zinc chelation, such as through alteration of the 
conformational state of the peptide.  We therefore tested for the ability of D7.2-123-B to 
enhance 1 WT and W170S GlyR function.  Unfortunately, we were unable to express 
functional heteromeric 1(W170S): receptors.  However, D7.2-123-B enhanced WT1 
homomeric and  heteromeric receptors to a similar degree, suggesting that it should 
be able to enhance homomeric 1 W170S GlyR function as well (Fig. 5.1).  We saw that 
D7.2-123-B enhancement was significantly decreased in W170S GlyRs compared to 
wildtype receptors, similar to the decrease of peptide enhancement seen in  receptors 
in the presence of tricine (Fig. 5.1).  This suggests tricine inhibition of peptide 
modulation is mediated through the chelation of zinc and not some effect of tricine on the 
peptides themselves.   
We next used the W170S receptor to probe for zinc’s ability to interact with other 
GlyR modulators, finding significantly reduced enhancement by inhalants in W170S 
GlyRs, suggesting that these modulators also interact with zinc to synergistically enhance 
receptor function (Fig. 5.2).  However, this was not true for GlyR enhancement by 
volatile anesthetics, which had similar effects in WT and W170S receptors, suggesting 
that there are some differences in how anesthetics enhance GlyR function, compared to 
ethanol and inhaled drugs of abuse. 
 Previous studies investigating zinc’s interactions with other GlyR modulators 
examined zinc concentrations ≤ 1 M.  However, much higher concentrations of zinc 
may be present after synaptic release.  We therefore investigated the effects of 10 M 
ZnCl2 on ethanol modulation (Fig. 5.3).  Interestingly, we saw that enhancement by 
ethanol was significantly decreased in WT receptors in the presence of 10 M zinc 
compared to standard MBS, where only ~45 nM zinc would be present. One possible 
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explanation is that occupation of the inhibitory zinc-binding sites inhibits the ability for 
ethanol to modulate the channel.  However, when we repeated this experiment with 
W170S receptors, which only exhibit zinc inhibition, 10 M zinc had no effect on 
ethanol modulation.  This experiment suggests that saturation of the zinc-enhancing site, 
not occupation of the inhibitory site, results in the decrease in ethanol’s enhancement 
seen in WT receptors.  While this seems counter-intuitive with the findings that lower 
concentrations of zinc act synergistically with ethanol to enhance GlyR function, these 
data fit nicely with a mechanism by which ethanol, in addition to modulating the channel 
on its own, increases the affinity for zinc at the GlyR-enhancing site.  The lower degree 
of ethanol enhancement seen in the presence of tricine reflects the ability of ethanol itself 
to enhance GlyR function.  In the presence of lower concentrations of zinc, ethanol’s 
enhancement appears larger because in addition to its own modulation of channel 
function, it increases the affinity of zinc binding to the GlyR-enhancing site, thereby 
increasing enhancement by zinc as well.  However, in the presence of higher 
concentrations of zinc, the GlyR-enhancing zinc site is already saturated and once again 
the effects that are seen are those produced by ethanol alone.  The similar results 
observed with TCE suggest that inhalants interact with zinc by the same mechanism.  
However, halothane enhancement was unaffected by zinc concentration in WT and 
W170S receptors, providing further support that volatile anesthetic modulation of GlyRs 
is not affected by the presence of zinc and that not all of these allosteric modulators act 




Chapter 6: General discussion, conclusions, and future 
directions 
6.1- Overview 
Pharmacological enhancement of GlyR function has been proposed as a 
promising strategy for the treatment of both alcoholism and chronic inflammatory pain 
(Li et al., 2012; Molander et al., 2005; Molander and Soderpalm, 2005a; Xiong et al., 
2011, 2012).  However, the lack in specificity of currently known GlyR modulators has 
hindered the development of promising candidate molecules for GlyR-targeted 
therapeutic applications.  Indeed, most positive allosteric modulators of GlyR function, 
such as ethanol, cannabinoids, and zinc, are capable of affecting a wide variety of other 
molecular targets.  Further, the magnitude by which some modulators affect GlyR 
function is dependent upon the local concentration of zinc present at the receptor.  Since 
zinc is ubiquitous in the CNS, it is critical to account for any possible interaction between 
zinc and other GlyR modulators in order to have a clear understanding of how these 
molecules behave in vivo. The research presented in this dissertation expands on a 
recently-developed method to identify specific modulators of GlyR function, highlights 
the importance of accounting for zinc when characterizing novel GlyR modulators, and 
describes a possible mechanism by which modulators interact with zinc to enhance 
receptor function. 
 
6.2- Phage display for the discovery of novel modulators of GlyR 
function 
Tipps et al. (2010) reported the first use of phage display technology for the 
identification of allosteric modulators of a ligand-gated ion channel.  Utilizing 
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commercially available phage display libraries and a HEK cell based panning procedure, 
they were able to identify peptides capable of selectively enhancing GlyR function at low 
M concentrations.  In chapter 3, we expanded on this procedure in an attempt to identify 
peptides capable of selectivity modulating specific GlyR subtypes.  GlyR subunits can 
combine to form six possible subtypes: , , and  homomeric receptors or 
and  heteromeric receptors (Lynch et al., 2009).  While 3-containing receptors 
are thought to predominate in GlyR-mediated analgesia (Xiong et al., 2011, 2012), it is 
not entirely clear which subtypes are responsible for the behavioral and dopamine-
modulating effects of alcohol.  Therefore, subtype selective GlyR modulators could serve 
as valuable pharmacological tools in determining which GlyR subunits are important for 
various physiological functions, such as responses to ethanol. 
Recent behavioral studies of ethanol’s effects on GlyR mutant mice suggest that 
1-containing GlyRs regulate ethanol-induced motor activity and sedation while 2-
containing receptors seem the most important in mediating ethanol preference and 
consumption (Aguayo et al., 2014; Blednov et al., 2015; Findlay et al., 2002).  
Specifically, 2 GlyR knockout mice showed decreased voluntary ethanol consumption 
as assayed by a 24 hour two-bottle choice test (Blednov et al., 2015).  While this may 
seem counterintuitive to the findings that increased accumbal GlyR function decreases 
ethanol consumption and preference in rats (Li et al., 2012; Molander et al., 2005), it 
makes sense when considered in the context that GlyRs control ethanol-induced 
dopamine release and therefore gate the reward signal for consuming alcohol.  For 
example, if ethanol-induced dopamine release is significantly inhibited in 2-knockout 
mice, than they will not find ethanol as rewarding and therefore drink less than wildtype 
controls, as was seen by Blednov et al. (2015).  In support of the role of the 2 subunit in 
ethanol consumption, recent reports on GlyR transcript levels in rats identified the 2 
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subunit as the most highly expressed  subunit in the forebrain, including regions 
important in the rewarding properties of ethanol such as the nAc (Delaney et al., 2010; 
Jonsson et al., 2009, 2012).     
As we obtained peptides with selectivity for  and  compared to 
receptors, future phage display procedures targeting the  subunit are warranted.  If 
novel 2-selective GlyR-enhancing peptides were capable of reducing voluntary ethanol 
consumption, while the 1- and 3-selective peptides described here were not, this 
would validate the 2 GlyR subunit as the primary molecular target mediating ethanol 
intake.  However, due to the effectiveness of the presently-reported peptides to enhance 
 GlyR function, they may still serve as useful leads in the development of a novel 
medication for the treatment of chronic inflammatory pain.  Specifically, the deduced 
consensus sequences described in table 3.2 could be utilized in directing the production 
of novel phage display libraries in which each clone would display a variant of these 
sequences.  This would allow for the possible identification of higher potency peptides 
that may be able to enhance GlyR function in a clinically relevant range; i.e. low 
nanomolar concentrations. 
 
6.3- Zinc’s interactions with other allosteric modulators of GlyR 
function. 
Zinc is one of the most prevalent nutritionally-essential elements in the human 
body and is the most abundant trace metal in the brain (Watt 2013; Tapiero 2003).   Zinc 
is critical to the structure and function of a large number of macromolecules and is 
essential for over 300 enzymatic reactions (Tapiero, 2003).  Long known as a potent 
modulator of GlyR function, zinc is interesting in that it serves as a biphasic modulator of 
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the GlyR, enhancing GlyR activity at concentrations in the low nM to 10 µM range and 
inhibiting GlyR activity at higher concentrations (Laube et al., 1995).  Further, zinc 
influences the degree by which ethanol enhances GlyR function, increasing ethanol 
potentiation when nanomolar concentrations of zinc are present (McCracken et al., 2010, 
2013a,b). The ubiquitous nature of zinc, found both physiologically in the CNS and as 
contaminant in labware and reagents, makes it critical to account for the effects of zinc in 
studies of GlyR function and modulation.   
In chapter 3 we tested the hypothesis that peptide modulation of GlyR function 
was zinc-dependent, similar to modulation by ethanol.  The addition of tricine to our 
electrophysiological buffer significantly inhibited the ability of peptide modulators to 
affect receptor function, suggestive of zinc dependence.  However, these data did not 
discount the possibility that the addition of tricine might have effects on receptor 
activation or allosteric modulation apart from their abilities to chelate zinc.  For example, 
tricine could act itself as an allosteric modulator of GlyR function or it could somehow 
inhibit the ability of peptides to bind the channel, or conceivably even bind to the 
peptides themselves.  In order to alleviate this concern we investigated the utility of 
mutant GlyRs previously reported as insensitive to enhancement by zinc for the study of 
GlyR modulation in the absence of any effects from contaminating zinc (Chapter 4).  
While we were unable to confirm the previously-reported results of abolished zinc 
enhancement in  D80A and D80G GlyRs, we were able to confirm this for the  
W170S GlyR.  Using this mutant receptor, we confirmed that tricine itself does not 
appear to modulate GlyR function.  Further, ethanol enhancement of W170S receptors 
was similar to that of WT receptors when zinc was chelated with tricine, suggesting this 
mutant receptor can serve as an adequate model for studying GlyR modulation in the 
absence of co-modulation by contaminating zinc. 
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In chapter 5 we utilized the  W170S GlyR to address several open questions 
involving zinc.  First, we confirmed the zinc-dependence of peptide D7.2-123-B 
enhancement of GlyR function.  This suggests tricine’s effect on peptide modulation was 
due purely to the chelation of zinc and not any effect of tricine on the peptides 
themselves.  However, as every peptide behaves differently based on the chemical 
properties of its unique amino acid sequence, this conclusion should not be generalized to 
all peptides.  Secondly, we used the W170S receptor to screen for zinc-dependence in the 
action of volatile anesthetics and inhaled drugs of abuse at the GlyR.  Interestingly, we 
found that GlyR modulation by inhalants but not volatile anesthetics appears zinc 
dependent.  This is surprising as ethanol, inhalants, and volatile anesthetics all share an 
overlapping binding site (Beckstead et al., 2000; Mihic et al., 1997), and suggests that 
these modulators must interact with this binding pocket in different ways to enhance 
GlyR function.  However, there are no clear differences in the structures of volatile 
anesthetics compared to ethanol or inhalants that could account for their apparent 
difference in mechanism in relation to zinc (see page xviii).  Molecular dynamics 
simulations of how the positions of these modulators fluctuate within the binding pocket 
might identify key contacts necessary for the interaction between modulators and zinc.  
Finally, testing for the effects of higher concentrations of zinc on modulation of  WT 
compared to W170S GlyRs allowed us to deduce a mechanism by which molecules such 
as ethanol and inhalants interact with zinc to increase channel function.  Specifically, 
these compounds, besides being able to positively modulate receptor function on their 
own, also appear to increase the affinity of zinc to its GlyR-enhancing binding site, 
thereby increasing zinc enhancement of the channel as well.  However, as these 
experiments were not performed with peptides, it is unclear if their zinc-dependence is 
mediated through the same mechanism.  An alternative mechanism for zinc-dependence 
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of peptide action is that zinc could be important in maintaining peptides in their GlyR-
binding conformation.   
The local concentration of free zinc that is available to act on GlyRs in the CNS is 
unclear.  Tonic concentrations of zinc in human CSF are in the low nanomolar range, 
similar to what is found in our electrophysiological buffers (Frederickson et al., 2006b).  
However, zinc is also released synaptically, resulting in local concentrations of zinc that 
have been reported to range from 1-100 M (Frederickson et al., 2006a; Qian and 
Noebels, 2005; Vogt et al., 2000; Zhang et al., 2016).  Further, a recent report using 
artificial synapses created from cultured rat embryonic glycinergic neurons suggested that 
they may be capable of synaptically releasing zinc (Zhang et al., 2016).  Since 
modulators such as ethanol have the highest level of enhancement at nanomolar 
concentrations of zinc with decreased enhancement seen at M concentrations (See 
chapter 5; McCracken et al., 2013a,b), future studies should be directed at determining 
the extent of synaptically-released zinc’s involvement in endogenous modulation of the 
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